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ABSTRACT 
 
ALIA ABDUL-HAMID AL-TAYYIB:  Undiagnosed Chlamydial and Gonococcal Infections in 
an Emergency Department 
(Under the direction of William C. Miller, MD, PhD, MPH) 
 
 
Chlamydial and gonococcal infections are the two most commonly reported sexually 
transmitted infections in the United States.  Screening programs in clinics, schools, and 
communities detect a substantial burden of infection.  Extension of current recommended 
guidelines has been suggested through expanding screening settings.  Emergency 
departments have been proposed as potentially promising venues for screening 
interventions.  The purpose of this dissertation is to investigate the utility and obstacles 
associated with chlamydial and gonococcal screening in an emergency department.  To 
examine this issue, we analyzed data from a cross-sectional and short duration prospective 
cohort study of patients aged 18 to 35 years attending a busy urban emergency department.  
The overall prevalence of infection in this population was 9.6%.   
 
Separately for males and females, we developed predictive models and applicable clinical 
risk scores for chlamydial and gonococcal infections combined and for chlamydial infection 
alone.  Age was the strongest predictor of infection in all four models.  We then used the 
sensitivities and specificities of the clinical risk scores to examine the trade-off in 
misclassification errors across varying prevalence of infection.  Results of this analysis 
suggest that the consequences of undetected chlamydial and/or gonococcal infection must 
substantially outweigh the costs of screening to justify incorporating routine screening into 
emergency department services.  
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In independent models, we evaluated the influence of healthcare coverage status and 
reporting the emergency department as the main source for healthcare on the risk of not 
receiving treatment and follow-up services for infections identified in the emergency 
department.  Antibiotic use in the three months prior to the emergency department visit 
appears to modify both of these associations.  Lastly, we described the geospatial 
distribution of the detected infections and their treatment outcomes. 
 
As screening programs move into emergency departments, serious consideration must be 
given to the costs associated with unnecessarily screening a significant number of patients 
to detect infections.  In addition, consideration must be given to ensuring appropriate 
treatment and follow-up for all detected infections. 
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CHAPTER ONE:  OVERVIEW 
 
 
Infection with Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) are the two most 
commonly reported sexually transmitted infections (STI) in the United States.1  The high 
prevalence of asymptomatic infection and the potentially serious clinical consequences of 
untreated infection necessitate comprehensive screening programs in vulnerable 
populations.  Recent expansion of screening efforts and the use of more sensitive diagnostic 
tools have resulted in a dramatic increase in reported cases and rates.  However, despite 
expanded screening efforts, the majority of infections remain undiagnosed.2   
 
The majority of screening programs are based in clinics, schools, and communities.3  In 
recent years, Emergency Departments (ED) have been proposed as promising settings for 
screening interventions.4  EDs often serve as primary care sites for persons who do not 
have regular access to healthcare, typically inner-city and difficult-to-reach patient 
populations.5  Many of those at highest risk for STIs do not have access to regular 
healthcare.  Therefore, populations at highest risk may be accessible though Emergency 
Departments.   
 
Detection of STIs necessitates treatment of the infection and notification of the infected 
individual’s sexual partner(s) to prevent further transmission.  Identifying characteristics 
associated with a higher likelihood of follow-up with treatment and partner notification after 
infections are identified can provide useful information for disease control and prevention.  In 
 
 
2 
addition to demographic and behavioral information, geographic data can provide visual 
representation of how infections are distributed.   
 
This dissertation aims to assess the effectiveness of screening for current undiagnosed 
chlamydial and gonococcal infections in an ED, to evaluate factors associated with not 
receiving treatment or follow-up services for ED-identified infections, and to characterize the 
geographic distributions of infections identified in the ED. 
 
For these analyses, we used data from the CONTACT study which was a cross-sectional 
and short duration prospective cohort study conducted between November 2002 and 
February 2005 in Baltimore, MD.  The study was designed to evaluate the public health and 
clinical consequences of chlamydial and gonococcal infections detected by nucleic acid 
amplification tests (NAAT).  Patients attending the Johns Hopkins Adult Emergency 
Department were screened for Ct and GC using NAATs during the ED screening phase of 
the study.  Patients testing positive for either infection were re-contacted and referred to the 
Johns Hopkins General Clinical Research Center (GCRC) for the follow-up phase of the 
study.  Recent sexual partners of infected patients were also recruited for follow-up phase. 
 
1.1. Specific Aim One 
Aim 1a: To develop and evaluate risk score algorithms, using demographic 
and behavioral characteristics, to predict current undiagnosed chlamydial and 
gonococcal infection in an Emergency Department population. 
 
Aim 1b:  To assess the performance of the algorithms across varying 
prevalence of infection. 
 
Aim 1c:  To validate the performance of previously developed criteria derived 
in the same ED setting. 
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Hypotheses:  (1) It is possible to predict undiagnosed Ct and GC in an ED with reasonable 
accuracy using selected screening criteria.  (2)  Performance of the algorithms will change 
with varying prevalence of infection.   
 
Rationale:  In 1998, Mehta and colleagues identified age 25 years or younger, having more 
than one sexual partner in the past 90 days, and a history of STI as predictive risk factors for 
chlamydial and/or gonococcal infections in adults 18 to 31 years of age attending the Johns 
Hopkins Adult Emergency Department.6  This data is often cited as evidence for expanding 
routine Ct and GC screening into EDs.  However, the validity of the results may be 
compromised by limitations in study design, sample size, and analytic methods.  This 
dissertation research applied vigorous analytic methods to develop predictive models and 
applicable risk score algorithms to predict undiagnosed infection in an ED setting.  In 
addition, we evaluated the algorithms’ performance across varying levels of infection 
prevalence.  The availability of ED-specific screening criteria with known performance 
characteristics at varying prevalence of infection provides a useful tool for ED programs 
considering incorporating Ct and GC screening into routine activities.  
 
Overview:  Using demographic and behavioral data collected during patients’ ED visit, we 
developed predictive models to identify undiagnosed chlamydial and gonococcal infections.  
We used our predictive models to develop risk score algorithms which have more practical 
applicability in an ED setting.  We evaluated algorithm performance using sensitivity and 
specificity characteristics at different risk score cutoffs and examined the trade-off between 
misclassification errors at varying levels of infection prevalence.  Positive results from the 
NAATs served as the measure of undiagnosed infection with Ct and GC.  Our final 
algorithms are presented in a manner to easily facilitate transition from research to 
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implementation for emergency departments considering integration of screening services 
into their routine provision of care. 
 
1.2. Specific Aim Two 
Aim 2a: To examine the influence of two main factors of interest, healthcare 
coverage and reporting the Emergency Department as the main source for 
healthcare, on the risk of not receiving treatment or follow-up services for ED-
identified chlamydial and gonococcal infections. 
 
Aim 2b:  To describe the geospatial distribution of chlamydial and gonococcal 
infections identified in the ED. 
 
Hypotheses:  (1) Patients lacking healthcare coverage will be less likely to receive treatment 
and follow-up services for their ED-identified infection.  (2)  Patients reporting the ED as their 
primary source for healthcare will also be less likely to receive treatment and follow-up 
services for their infection.  (3) There will be a clearly defined cluster of infection in the 
immediate vicinity of the ED.   
 
Rationale:  Few studies have assessed the factors associated with the treatment and follow-
up of patients screened for Ct and GC in ED settings.  Identifying factors that may influence 
the risk of not receiving treatment or follow-up services for an identified infection could help 
target presumptive treatment to those at highest risk for transmitting infection or potentially 
developing complications from untreated infections.  In addition, mapping the distribution of 
infections provides a method to visualize disease patterns.  The geographic epidemiology of 
gonococcal infections identified in Baltimore’s two STI clinics and non-STI clinic providers 
has been described previously.7, 8  However, the geographic epidemiology of chlamydial 
infections in Baltimore has not been described.  This research will provide updated 
information regarding the geographic distribution of chlamydial and gonococcal infections 
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identified in an emergency department setting that serves a population at elevated risk of 
infection yet is more representative of the general population that an STD clinic population. 
 
Overview:  Using data collected during patients’ ED visit and the status of their treatment 
outcome, we examined the association between two healthcare access measures, 
healthcare coverage status and accessing the ED as the main source for healthcare, and 
patients’ likelihood of not receiving treatment or follow-up services for their infection.  We 
also investigated the potential modifying and confounding effects of other individual 
characteristics and behaviors on these two main associations.  Additionally, using 
Geographic Information Systems (GIS), we mapped the geospatial distribution of chlamydial 
and gonococcal infections identified in the ED.  We created maps comparing patients who 
received treatment and follow-up services for their ED-identified infections and patients who 
did not receive treatment.  Finally, we examined travel distance to the ED as a potential 
indicator of not receiving treatment or follow-up services. 
 
  
 
CHAPTER TWO:  BACKGROUND 
 
 
2.1.  Epidemiology of Chlamydial and Gonococcal Infections 
Infection with Chlamydia trachomatis and Neisseria gonorrhoeae can lead to serious 
reproductive sequelae.  In women, untreated chlamydial and gonococcal infections can 
ascend from the vagina or cervix into the upper genital tract and cause infections in the 
endometrium, fallopian tubes, and contiguous structures resulting in pelvic inflammatory 
disease (PID).  The tubal scarring associated with PID can lead to complications such as 
infertility, ectopic pregnancies, and chronic pelvic pain.9  If these infections are not treated 
adequately, 20% to 40% of Ct infected women and 10% to 40% of GC infected women may 
develop PID.1  However, accurate estimates of PID and tubal infertility resulting from 
chlamdyial and gonococcal infections are difficult to attain due to the complexity of making a 
definitive diagnosis for either condition.  Furthermore, infants born to infected mothers are 
susceptible to conjunctivitis and neonatal pneumonia; and in men, untreated Ct and GC 
infections increase the risk of urethritis, prostatitis, and epididymitis.10 
 
Chlamydial and gonococcal infections are the two most commonly reported STIs in the 
United States.1  In 2005, approximately one million cases of chlamydial infection and 
350,000 cases of gonorrhea were reported to the Centers for Disease Control and 
Prevention (CDC).1  Although the prevalence of gonococcal infections is considerably lower 
than that of chlamydial infections, presumably due to its slightly more symptomatic nature, 
the prevalence of gonorrhea remains unacceptably high for an infection that produces 
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significant clinical sequelae if left untreated.  Moreover, these estimates only reflect the 
burden of reported infections.  Assuming a significant number of infections are not reported 
or even diagnosed, the true burden of infection increases to an estimated 2.8 million 
Americans infected with Chlamydia trachomatis and 718,000 infected with Neisseria 
gonorrhoeae each year.11 
 
Approximately 70% of chlamydial and 50% of gonococcal infections in women are 
asymptomatic and, if undetected and untreated, can lead to serious health consequences.12-
14  These infections are slightly more symptomatic in men; nonetheless, up to half of 
chlamydial infections in men are asymptomatic.15, 16  In a study of 16 to 22 year old women 
attending a reproductive health clinic, 80% were aware that a person could have an STI 
without having symptoms.17  However, this knowledge does not translate into actively 
seeking screening services by the vast majority of the population.  To complicate matters 
further, when symptoms are present, the non-specific nature of the clinical signs can make 
diagnosis difficult.  Without vigorous public health interventions, the majority of 
asymptomatic infections will remain untreated, allowing for persistent infection, potential 
transmission to sexual partners and, in some individuals, progression to serious 
complications. 
 
In both men and women, inflammatory STIs such as chlamydial and gonococcal infections 
may increase susceptibility to and transmission of the human immunodeficiency virus 
(HIV).18-22  Infection with Ct and GC appears to increase the prevalence of HIV shedding and 
viral load in genital secretions making these infections predictable indicators of HIV 
infectiousness.23  For example, among HIV-infected men, gonococcal infection is associated 
with concentration levels of HIV in semen that are as much as ten times higher than HIV 
concentration levels in men without gonorrhea.24  Although the sequelae of chlamydial and 
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gonococcal infections are serious enough on their own to warrant significant public health 
interventions, the epidemiologic synergy between these two inflammatory STIs and HIV is 
an even more compelling reason to direct efforts and resources towards detecting these 
infections. 
 
2.2. Screening for Chlamydial and Gonococcal Infections 
Screening programs detect a substantial burden of chlamydial and gonococcal infections 
and reduce adverse health outcomes.  Due to the asymptomatic nature of chlamydial and 
gonococcal infections, voluntary care-seeking to resolve STI-related symptoms is not likely 
to lead to detecting the greater part of infections.  Thus, screening programs are a critical 
component of expanding early detection and treatment of these bacterial infections.  In 
areas where large-scale screening programs for chlamydial infections have been in place for 
several years, the programs’ effectiveness in reducing prevalence has been 
demonstrated.25, 26  In the pivotal clinical trial most often cited as evidence for the 
effectiveness of screening to prevent adverse health outcomes caused by chlamydial 
infection, women who were screened for Ct were 56% less likely to develop incident PID at 
the end of one year of follow-up when compared to women who were not screened, among 
18 to 34 year old enrollees of a health maintenance organization.27 
 
Current recommendations for chlamydial infection limit screening to sexually active females. 
The United States Preventive Services Task Force (USPSTF) and the Centers for Disease 
Control and Prevention strongly recommend routine screening for chlamydial infection for all 
sexually active women 25 years or younger, regardless of symptoms.28, 29  In addition, both 
agencies recommend routine screening of all women who have had more than one sexual 
partner, have been previously diagnosed with an STI, and women who do not use condoms 
consistently and correctly, regardless of age.  In CDC’s 1998 Guidelines for Treatment of 
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Sexually Transmitted Diseases, males were included in the recommendation to screen all 
sexually active adolescents for chlamydial infection regardless of symptoms.30  However, at 
the current time, no recommendations exist for Ct screening in asymptomatic males due to 
the lack of evidence to support the effectiveness of screening to prevent acute infections or 
complications in men.28  While the overall reported rate of chlamydial infection was over 
three times higher for women compared to men in 2005, the rate of infection among men 
increased by 43.5% between 2001 and 2005 compared to a 15.6% increase among women 
for that same time period.1  This increase in rates of infection among men may warrant 
consideration of including males in screening recommendations. 
 
Analysis of the 1999-2000 Health Plan Employer Data and Information Set (HEDIS) 
determined that, despite increases in screening by both commercial and Medicaid health 
insurance plans, screening rates are low.31  In 2001, among sexually active females aged 16 
to 26 enrolled in commercial health plans, 26% were screened for chlamydial infection while 
38% of 16 to 26 year olds in Medicaid plans were screened.  These proportions represent 
increases of 6% and 10%, respectively, over the percentages screened in 1999.  Despite 
the increase, these percentages fall well below the recommendation to routinely screen all 
sexually active females younger than 26 years of age.   
 
In 2005, the USPSTF issued the recommendation that clinicians screen all sexually active 
women at increased risk of infection with Neisseria gonorrhoeae.  Risk factors for gonorrhea 
include young age, a history of previous gonorrhea infection or other STIs, new or multiple 
sexual partners, inconsistent condom use, sex work and drug use.  However, the USPSTF 
did not find sufficient evidence in the current literature to recommend screening for 
gonococcal infections in men at increased risk.32  While national guidelines do not currently 
exist for gonococcal screening, the CDC recommends that studies of selective screening 
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criteria for gonococcal infections be performed.33  Nevertheless, the CDC recommended in 
its 2002 Clinical Treatment Guidelines that all sexually active men who have sex with men 
be screened at least once annually for genital gonorrhea as well as pharyngeal and rectal 
infection if they are at risk for exposure.29 
 
The Advisory Committee for HIV and STD Prevention (ACHSP), which provides oversight 
and guidance to the CDC in the prevention of HIV and other STIs, endorses current 
screening recommendations and extends them to include annual chlamydial and 
gonococcal screening of all sexually active females 25 years and younger in healthcare 
settings where screening is feasible such as family planning and prenatal clinics, walk-in 
and school-based clinics, correctional facilities, primary-care provider offices, and 
emergency departments.  In addition, the ACHSP extends recommendations to include 
annual screening of all sexually active men in settings and populations in which the 
prevalence of infection is greater than 2%.  The ACHSP also broadens the 
recommendations to include at least annual screening of older, higher-risk females and 
males (e.g. persons with a history of STIs or more than one sex partner per year and 
persons from communities with high rates of STIs) visiting healthcare providers for any 
reason.23 
 
NAATs ability to detect Chlamydia trachomatis and Neisseria gonorrhoeae from specimens 
collected without invasive pelvic exams or intraurethral swabs facilitates screening in non-
clinic settings.34-40  The Food and Drug Administration (FDA) has cleared the majority of 
commercial NAATs for Ct and GC detection in endocervical swabs from females, urethral 
swabs from males, and urine specimens from both males and females, thus facilitating 
expansion of screening efforts into non-clinic settings.41  A recent review describing Ct and 
GC testing initiatives in schools, communities, and home settings highlights the opportunity 
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provided by NAATs to reduce rates of chlamydial and gonococcal infections in populations 
currently missed by clinic-based control efforts.  However, the review also underscores the 
challenges posed in accurately defining the target populations most likely to benefit from 
non-clinic screening.3 
 
2.3. Cost Effectiveness of Screening Programs 
The economic costs of chlamydial and gonococcal infections are considerable.  An analysis 
estimating the direct medical costs of chlamydial and gonococcal infections among person 
aged 15 to 24 approximated the cost at $248.4 million and $77 milliona, respectively.42  
These direct cost estimates include expenses for treating acute infections and the sequelae 
of untreated or inadequately treated infections. 
 
Reducing the prevalence of infection and subsequent clinical sequelae of chlamydial and 
gonococcal infections through screening activities is cost-effective and occasionally cost-
saving.14, 43-46  The CDC estimates that for every $1 spent on screening activities 
approximately $12 in costs associated with complications from chlamydial and gonococcal 
infections could be saved.47  Additionally, a recent cost-effectiveness analysis concluded 
that annual screening of women 15 to 29 years old followed by semiannual screening of 
those with a history of infection was the most effective and economical strategy.48 
 
Additional cost savings may be realized through averted HIV cases.  The epidemiologic 
synergy between STIs and HIV necessitates consideration of the impact of STI control 
programs on HIV when evaluating the cost-effectiveness of any STI prevention program.49  
The costs associated with averted treatment for prevented cases of HIV should be included 
in cost-effectiveness evaluations of STI screening programs.  Using a mathematical model 
                                                 
a Adjusted to 2002 dollars 
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to approximate the probability that a given STI would facilitate HIV transmission from an 
HIV-infected person to his or her partner, an estimated 3249 cases of new HIV infection 
were attributed to chlamydial infection and 430 new HIV cases were attributed to gonorrhea.  
The direct medical costs of HIV cases attributed to chlamydial and gonococcal infections 
were estimated at $633.6 million and $83.8 millionb, respectively. 
 
To date, only one study has examined the cost-effectiveness of providing chlamydial and 
gonococcal screening services in a high risk ED.50  The study compared five strategies: (1) 
standard ED practice which depended on the clinician’s decision to screen or treat based on 
history and physical examination; (2) universal screening of all 18 to 31 year olds with no 
standard ED practice; (3) selective screening of all patients with any risk factor in addition to 
standard ED practice; (4) universal screening of all 18 to 31 year olds combined with 
standard ED practice; and (5) mass treatment of all 18 to 31 year olds with no standard ED 
practice.  The authors concluded that the cost-effectiveness of screening was maximized 
when combined with standard ED practices.  In addition, they concluded that universal 
screening was more cost-effective than selective screening when the combined prevalence 
of chlamydial and gonococcal infections ranged from 7% to 17.5%.  However, the analysis is 
limited by the assumption that funds for chlamydial and gonococcal screening in the ED had 
already been allocated.  In one cost-effectiveness analysis restricted to gonococcal 
infections among women aged 15 to 29 in urban EDs, the authors concluded that, across a 
broad range of assumptions, screening with urine-based NAATs does provide cost 
savings.51 
 
2.4. Access to Healthcare and ED Utilization 
                                                 
b Adjusted to 1996 dollars 
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Patient characteristics have been the focus of most ED utilization studies which show that 
the ED is used disproportionately by patients receiving Medicaid support, patients lacking a 
primary care physician, members of ethnic and racial minorities, and other “vulnerable” 
groups.52, 53  Higher ED use by certain segments of the population suggests limited access 
to a regular source of healthcare for these groups. 
 
Disparities in access to healthcare exist, forcing persons who lack insurance or are publicly 
insured to seek care at the ED.  According to the National Survey of America’s Families 
(NSAF), 17% of adults made one or two ED visits and 3% made three or more visits to the 
ED during a 12 month period between 1997 and 1999.54  Frequent ED users may be more 
likely to lack insurance and to use the ED as a source of regular medical care.  However, 
the NSAF suggests that the publicly insured, which includes Medicaid and any other state-
specific program, are overrepresented among ED users.  The NSAF also suggests that 
frequent ED users are more likely to be African American and of lower socioeconomic status 
when compared to occasional ED users. 
 
Individuals at higher risk for STIs may be more likely to seek care at EDs for STI-related 
complaints.  The average annual rate of gynecologic visits made to EDs by women aged 15 
to 44 years is 24.3 visits per 1000 women (95% CI: 22.0, 26.6 per 1000) according to data 
from the 1992-1994 National Hospital Ambulatory Medical Care Survey.55  Roughly half of 
the 1.4 million visits to the ED made by women of reproductive age were for conditions 
related to the clinical sequelae of sexually transmitted pathogens.  For lower genital tract 
infections, younger women (ages 15 to 24 years) visited an ED 2.9 (95% CI: 2.1, 3.6) times 
as frequently as older women (aged 25 to 44 years).  In addition, African American women 
visited the ED 6.6 (95% CI: 4.7, 8.6) times as often as Caucasian women for lower genital 
tract infections.  These differences in diagnosis are likely due to the underlying difference in 
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disease prevalence in each group but could also be indicative of unmeasured risk factors 
such as accessibility to and acceptability of primary health care services.  Younger women 
had a higher rate of overall visits to the ED than older women (RR=1.4, 95% CI: 1.3, 1.4) 
and African American women had a higher overall rate than Caucasian women (RR=1.8, 
95% CI: 1.6, 2.1) indicating that the disparity in patterns of health care seeking is not limited 
to gynecologic visits. 
 
In recent years, Emergency Departments have been proposed as promising settings for 
screening interventions.  Despite the potential operational hurdles in implementing and 
sustaining screening programs in a busy ED, data suggest that EDs may represent high-
yield screening venues with the prevalence of detected infections ranging from 8% to 11% 
for chlamydial infections and 2% to 9% for gonococcal infections.4  Given that the 
prevalence of Ct and GC in persons tested in EDs 6, 40, 56, 57 is comparable to the prevalence 
of infection identified in traditional clinical venues and that EDs serve a population that may 
be medically marginalized and potentially at higher risk for STIs and HIV, ED screening may 
warrant being moved to the forefront of STI screening programs. 
 
2.5. Follow-up Services 
The current lack of a point-of-care test with acceptable sensitivity and specificity may lead to 
problems of over- and undertreatment.  Due to the largely asymptomatic nature of both 
chlamydial and gonococcl infections, early detection and diagnosis can be difficult.  
Inadequate clinical judgment combined with the lack of an accurate point-of-care test have 
lead to empirically treating patients who are not actually infected and not treating patients 
who are infected in ED settings.58, 59  Undertreatment leads to increased likelihood of 
disease transmission and progression of clinical sequelae such as PID.  With chlamydial 
infections, undertreatment can also lead to recurrent or persistent infections.60-62  On the 
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other hand, overtreatment is an issue of concern due to the unnecessary emotional trauma 
associated with being diagnosed with an STI.  In addition, drug resistance can occur with 
some gonococcal infections.63, 64 
 
Data supporting the integration of STI screening services in EDs are principally derived from 
studies that have relied on dedicated research staff for recruiting, interviewing, screening, 
and providing follow-up test results and treatment.6, 40, 56  Development of algorithms to 
presumptively treat those at highest risk during their ED visit has been suggested with the 
caveat that such algorithms may be nonspecific and result in needlessly treating a 
significant number of patients.4  Despite these limitations, EDs do provide a venue to reach 
persons who may not seek regular healthcare and may also be at higher risk for STI.  In 
addition, screening for Ct and GC in ED settings appears to be acceptable to adolescents 
aged 14 to 20, the demographic group at highest risk.65 
 
Follow-up services and treatment for infections identified in EDs benefit from integration with 
local health departments.  A recent evaluation of a follow-up program for females presenting 
to an ED in Philadelphia, organized by the municipal department of health, indicated that the 
department of health was able to successfully follow-up and treat 82% of infections that 
were not identified and appropriately treated in the ED.66  In settings where it is feasible to 
integrate services with local health departments, screening for Ct and GC can facilitate 
provision of STI services to difficult-to-reach populations. 
 
2.6. Current State of Knowledge and Research Gaps 
Although EDs have potential as high yield venues for detection of chlamydial and 
gonococcal infections, the feasibility of screening programs in EDs remains unclear.  The 
evidence to date indicates that the prevalence of infections identified in EDs, 8% to 11% for 
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chlamydial infections and 2% to 9% for gonorrhea, is high enough to warrant screening in 
this population.6, 40, 56, 67-69  However, the data supporting the feasibility of screening in EDs 
are limited by the small number of studies.  Data are also limited by the fact that these 
studies have depended on dedicated study staff to conduct screening activities and have not 
evaluated the feasibility of fully incorporating screening services into routine ED practice.  In 
addition, only one study has examined the utility of ED-specific screening criteria when 
applied to a different population.70  Information on the follow-up and treatment of infections 
identified in an ED setting is also limited by the same reasons, small number of studies and 
incomplete integration into regular ED activities.  
 
The geospatial distribution of infections identified in an ED setting has not been adequately 
explored.  To date, mapping activities have relied on infections identified in traditional testing 
sites such as STI clinics and through surveillance programs.7, 8, 71-74  Mapping infections that 
are primarily asymptomatic and do not prompt health care seeking, and therefore detected 
through population-based screening efforts, has not been thoroughly undertaken.  
Describing the potential differences in the geographic epidemiology of infections detected in 
different testing and screening venues may help inform public health interventions. 
 
To address some of these research gaps, we systematically examined predictors of 
infections that could potentially be detected in ED settings.  We developed and tested 
several risk score algorithms to detect chlamydial and gonococcal infections in an ED.  We 
examined the performance of criteria previously derived from a similar ED population by 
applying the previous criteria in our study population.  We also evaluated the performance of 
our developed algorithms at varying prevalence of infection to assess their applicability to 
different ED populations and to identify the optimal screening policy based on the 
prevalence of infection.   
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Furthermore, we examined factors associated with not receiving treatment or follow-up 
services for infections identified in an ED.  To identify the influence of healthcare access on 
the likelihood of not receiving treatment or follow-up for Ct and/or GC infection, we 
examined separately the association between healthcare coverage and the risk of not 
receiving treatment or follow-up and the association between reporting the ED as the 
primary source for healthcare and not receiving treatment and follow-up services for an ED-
identified infection.  Given the limited resources in most EDs, it may not be feasible for ED 
staff to follow-up all infections that are detected through ED screening.  Therefore, 
identifying patients not likely to return for follow-up or to seek treatment elsewhere can help 
target those patients most likely to benefit from more intense counseling on the importance 
of returning for treatment or presumptive treatment for patients with a reasonably high 
predictive probability of being infected. 
 
In addition, we improved upon the existing geographic epidemiology of Ct and GC infections 
in Baltimore, MD.  Our maps provide a visual representation of Ct and GC infections 
identified through screening activities in a busy urban ED.  Because we excluded patients 
who were seeking care at the ED for STI-related symptoms, these geographic distributions 
may be more representative of the true distribution of infection in the general population.   
 
 
  
 
CHAPTER THREE:  RESEARCH DESIGN AND METHODS 
 
 
3.1. The CONTACT Study 
3.1.1 Overview 
The development of NAATs for the detection of chlamydial and gonococcal infections in self-
collected urine and vaginal swab specimens provides new opportunities for estimating the 
prevalence of infection in the general population.  The transmissibility and clinical 
consequences of NAAT-identified infections, however, are unknown.  The main research 
aims of the CONTACT study were to: (1) determine whether the probabilities of infection 
transmission are equivalent for Ct and GC infections detectable only by NAAT versus 
infections detectable by traditional testing procedures; (2) determine whether asymptomatic 
infections have an equivalent probability of transmission as symptomatic infections; and (3) 
examine the correlates of infections detected by NAAT versus traditional diagnostic tests. 
 
To address these aims, patients aged 18-35 attending the Johns Hopkins Hospitals 
Emergency Department underwent screening for chlamydial and gonococcal infections.  
Male participants were asked to provide a urine specimen for amplification testing; female 
participants were asked to provide a self-collected vaginal swab.  Participants testing 
positive for GC and/or Ct were re-evaluated using traditional diagnostic tests (culture and 
direct florescent antibody) for these infections and treated at the Johns Hopkins Hospitals’ 
GCRC.  Recent partners of infected participants were also contacted and tested for GC and 
Ct using NAAT and traditional assays.  DNA-sequencing was performed on specimens of 
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partners testing positive to determine if both individuals were infected with the same 
pathogen strain.   
 
This study was a collaborative effort between RTI International, Johns Hopkins University, 
the University of North Carolina at Chapel Hill, RAND, and the Urban Institute.   
 
3.1.2. Participant Recruitment and Enrollment 
Emergency Department Screening of Index Patients 
Adult patients attending the Johns Hopkins Hospital ED between November 2002 and 
February 2005 were approached by trained interviewers for enrollment in a two-phase 
cross-sectional and short duration prospective cohort study of STI transmission.  Patients 
were eligible for participation if they were between 18 and 35 years of age, English-
speaking, sexually active in the past 90 days, and self-reported no antibiotic use in the past 
30 days (see Section 3.1.3. for explanation of change in the eligibility criteria).  Patients who 
were critically ill or presenting to the ED for acute psychiatric symptoms or STI-related 
symptoms, and employees or students of Johns Hopkins were excluded.  The informed 
consent procedures emphasized that patients’ participation in the study would not affect the 
medical care they received in the ED.  In addition, participants were told that those who 
tested positive for GC and/or Ct would be contacted and their positive test result would be 
reported to the Baltimore City Health Department.  They were also informed that their 
partners would be contacted (without revealing the identity of the participant) if they tested 
positive.  Participants were administered a brief audio-computer assisted self-interview 
(ACASI) questionnaire which took approximately 15 minutes to complete.  
 
Participants were given instructions and supplies for self-collecting a urine specimen for Ct 
and GC testing.  Female participants also received instructions and supplies for vaginal 
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swab collection (also for Ct and GC testing).  Specimens were refrigerated until shipped to 
the UNC laboratory for processing and testing.  Specimens shipped to the UNC laboratory 
contained a study identification number and a gender identifier.  To capture complete 
information on antibiotic use, interviewers reviewed each patient’s ED medical chart at the 
end of the day to determine if the participant was treated with antibiotics or given a 
prescription for antibiotics during his/her ED visit.  If a participant received antibiotic 
treatment during the ED visit and his/her NAAT result was positive for GC and/or Ct, the 
participant was notified by the Disease Intervention Specialist (DIS) but not recruited into the 
follow-up phase of the study.  All patients participating in ED screening phase of the study 
received a $10 food coupon incentive. 
 
The research questions and analyses addressed in this dissertation focus mainly on data 
collected during the ED screening phase of the study.  Procedures from the follow-up phase 
are described to provide an overview of the entire study. 
 
Examination and treatment of NAAT Positive Patients 
Patients testing NAAT positive for GC and/or Ct were contacted by trained DIS and offered 
an examination, further testing, and treatment at the Johns Hopkins GCRC.  Subjects who 
returned to the GCRC were seen by the dedicated study Nurse Practitioner (NP).  The NP 
explained the follow-up visit and obtained written informed consent from patients willing to 
participate.  Consenting participants were asked to complete a detailed ACASI 
questionnaire on individual demographic characteristics, alcohol and illicit drug use, recent 
sexual partners, condom use, antibiotic use, STI history and symptoms, and utilization of 
health care services. The participant was examined by the NP and given the appropriate 
treatment for his/her diagnosis.  A urine specimen was collected and shipped to UNC for 
NAAT processing and testing.  The NP also collected swabs for testing using traditional 
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assays (2 endocervical and 2 vaginal swabs from females and 2 urethral swabs from 
males).  Female participants were also asked to provide a self-collected vaginal swab for 
GC and Ct NAAT.  Rapid detection tests for bacterial vaginosis and trichomoniasis were 
also performed.  Participants were asked to provide a blood specimen for future diagnostic 
evaluation of inflammatory response to these infections.  Participants who agreed signed an 
addendum to the consent for blood sample storage.  Participants who completed the follow-
up phase of the study at the GCRC were paid $40, $75 or $200 (incentive amount was 
increased throughout the study period to enhance participation) for their time and 
cooperation.   
 
Sexual Partners of NAAT Positive Patients 
All recent sexual partners of patients testing positive for GC or Ct by NAAT assay were also 
contacted and referred for a clinical examination and treatment by DIS in compliance with 
procedures recommended by the CDC for STI case management.  Specifically, trained DIS 
attempted to locate and inform partners regarding their potential exposure and explain the 
need for evaluation and treatment.  The DIS are trained to balance the need to inform of a 
potential infection with assurances of respondent confidentiality.  At no time was the identity 
of the referring partner revealed.  Partners were counseled on the importance of treatment 
and were provided with several options for receiving care.  These options included: the 
location and hours of the local free public health department clinic, a free clinic at the 
GCRC, or their private doctor.  If they chose to seek treatment at the GCRC, the DIS 
scheduled an appointment for them.  It was also explained that the partner would receive 
free care at the GCRC, regardless of whether or not he/she participated in the research 
study.   
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Partners who presented to the GCRC for examination and treatment were offered the 
opportunity to participate in the study by the dedicated study NP.  Partners agreeing to 
participate were consented and enrolled in the study by the NP.  Partners who did not wish 
to participate were administered a standard STI clinical examination, provided single-dose 
oral antibiotic treatment, and counseled, at no cost to the partner.  Partners who found it 
costly and logistically difficult to attend the GCRC but wished to participate in the study were 
offered a home visit to collect a specimen for GC and Ct testing (urine from males, vaginal 
swab from females) and to complete the ACASI questionnaire.   
 
Written informed consent was obtained from all participants.  A separate consent form was 
administered for participation in each phase of the study. The study protocol was approved 
by the Institutional Review Boards of RTI International, Johns Hopkins Hospitals, and the 
University of North Carolina at Chapel Hill.   
 
3.1.3. Changes in Protocol 
Incentive Increase for ED Screening 
Recruitment in the ED for the screening phase of the study began in November 2002.  
Initially, participants did not receive an incentive for participation in the ED screening phase 
of the study.  Because of low participation rates during the first few months of recruitment, 
the decision was made to offer participants a $10 food coupon for participation.  Changes to 
the Informed Consent forms were made and approval from all three institutional IRBs was 
obtained in March 2003.  
 
Eliminating Self-reported Antibiotic Use from Eligibility Criteria 
Initial eligibility criteria for participation in the ED screening phase included: (1) participants 
between the ages of 18 and 35, (2) self-reported sexual activity within the past 90 days, and 
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(3) self-reported non-use of antibiotics in the past 30 days.  Preliminary monitoring of study 
enrollment indicated that approximately one-third of patients attending the ED were between 
18 and 35 years old and approximately 70% of these age-eligible patients were approached 
by study interviewers during study recruitment hours (between 6:00am and 11:00pm, seven 
days a week, except for Thanksgiving, Christmas, and New Years Day).  Of the patients 
approached, nearly 85% reported sexual activity in the past 90 days and approximately 20% 
reported antibiotic use in the past 30 days.  An additional 15-20% of patients approached 
were not eligible for participation because they were Johns Hopkins employees, level-1 
patients, had enrolled previously, or were psychiatric or mental patients.  Ultimately, only 
one-third of 18 to 35 year old patients approached were eligible for study participation. 
 
In attempts to boost study enrollment, the criterion of self-reported non-use of antibiotic use 
in the past 30 days was eliminated.  This change in eligibility criteria was supported by 
findings from a study conducted by one of Project CONTACT’s co-investigators in which STI 
outcomes between those who reported antibiotic use in the 30 days prior to screening and 
those who reported not taking antibiotics during the prior 30 days did not differ significantly.   
 
The eligibility criterion of self-reported non-use of antibiotics was eliminated in May 2003 
and appropriate changes to the Informed Consent forms were made and IRB approval from 
the collaborating institutions was obtained.  Patients who were treated with antibiotics during 
their ED visit remained ineligible for participation.  In addition, patients who received 
antibiotic treatment subsequent to enrollment in the ED screening phase of the study were 
not eligible for participation in the follow-up phase. 
 
Switch from LCR to PCR in Laboratory Testing 
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From the time of study initiation in November 2002 until June 2003, the ligase chain reaction 
(LCR, Abbott Laboratories) NAAT was used to test urine specimens collected from all 
participants.  In addition to a urine specimen, female participants provided self-collected 
vaginal swabs which were tested using the polymerase chain reaction (PCR, Roche 
Diagnostics) NAAT.   
 
In June 2003, Abbott Laboratories discontinued production of the LCR GC/Ct testing kits 
due to several reagent lots failing the analytical sensitivity described in the product insert 
during routine quality assurance testing.75  The UNC Microbiology Laboratory had a limited 
“back-up” supply and thus continued using the LCR to test all urine specimens until July 
2003.  Because detection of Neisseria gonorrhoeae from female urine specimens using 
PCR is not approved by the Food and Drug Administration (FDA), the study discontinued 
collecting urine specimens from female participants.   
 
Beginning in August 2003, female participants were asked only to provide self-collected 
vaginal swabs during their initial screening in the ED.  Detection of Chlamydia trachomatis 
from self-collected vaginal swabs is FDA-approved and detection of Neisseria gonorrhoeae 
from self-collected swabs was validated by the UNC laboratory.  According to Clinical 
Laboratory Improvement Amendments (CLIA) regulations, a clinical laboratory may use and 
report results of laboratory tests that are not FDA-approved if the laboratory independently 
validates the performance of the assay or collection method.  Male participants continued to 
provide urine specimens which were tested using PCR. 
 
Study quality and participant care were not impacted by this protocol change.  The 
sensitivities and specificities of the LCR and PCR for detecting GC and Ct are similar.  In 
addition, response rates were similar for females providing urine specimens (85%) and 
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females providing self-collected swabs (87%) at the time when this protocol change was 
implemented. 
 
3.1.4. Study Population 
Only participants who completed the ACASI screening questionnaire in the ED and provided 
a urine or self-collected vaginal swab specimen with a valid test result are included in the 
analyses (n=5,537; 89%).  Of the 6,195 patients who consented to participate, 495 (8%) 
patients did not complete the ACASI questionnaire, 82 (1.3%) patients did not provide a 
specimen, and 86 (1.4%) patients provided a specimen which was compromised and not 
tested (e.g. specimen leaked during transport).   
 
A total of 5,537 patients completed the ACASI questionnaire and provided a self-collected 
vaginal swab or urine specimen which yielded a valid test result.  Of these participants, 534 
(9.6%) patients tested positive for either Ct or GC or both.  DIS attempted to contact all 
patients identified as infected during their ED visit.  Of the infected patients, 278 (52%) 
received treatment and follow-up services at the GCRC, 87 (16%) received treatment during 
their ED visit, and 63 (12%) reported receiving treatment elsewhere (either at the local 
health department or at their primary care physician).  DIS were unable to locate 83 (16%) 
infected patients and 21 (4%) patients refused treatment.  See Figure 3.1 for flow of study 
participants.   
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3.2. Research Design for Specific Aim 1 
Aim 1a: To develop and evaluate risk score algorithms, using demographic 
and behavioral characteristics, to predict current undiagnosed chlamydial and 
gonococcal infection in an Emergency Department population. 
 
Aim 1b:  To assess the performance of the algorithms across varying 
prevalence of infection. 
 
Aim 1c:  To validate the performance of previously developed criteria derived 
in the same ED setting. 
 
3.2.1. Rationale for Selected Outcome Measures: Aim 1a 
We evaluated the utility of screening for chlamydial and gonococcal infections in an ED 
setting for two key reasons.  First, the development of highly accurate NAATs to detect Ct 
and GC using only a urine specimen or a self-collected vaginal swab has led to the 
extension of screening services into non-clinical settings.  Emergency Departments often 
serve as primary care sites for persons who do not have regular access to healthcare.  
Therefore, populations at highest risk may be accessible through ED settings.  Second, 
chlamydial and gonococcal infections are primarily asymptomatic or present with non-
specific symptoms which necessitates the need for screening programs.  To examine the 
utility of screening for Ct and GC in a busy ED, we developed and evaluated ED-specific risk 
score algorithms to predict undiagnosed infections. 
 
3.2.2. Outcome Measures: Aim 1a 
Four outcomes were assessed:  
1) Infection with Chlamydia trachomatis among females as measured by a positive LCR 
from urine specimens or a positive PCR from self-collected vaginal swabs 
2) Infection with Chlamydia trachomatis among males as measured by a positive LCR 
or PCR from urine specimens 
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3) Infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae among females 
as measured by a positive LCR from urine specimens or a positive PCR from self-
collected vaginal swabs, and 
4) Infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae among males as 
measured by a positive LCR or PCR from urine specimens. 
 
Our decision to evaluate these four models separately was motivated by two fundamental 
reasons.  First, there are inherent differences in the clinical consequences of undetected 
and untreated infections between females and males and a higher frequency of 
asymptomatic infections among females which require gender-specific screening criteria.  
Second, screening for gonorrhea is generally not recommended in settings where 
chlamydial screening is not already offered because the prevalence of chlamydial infection 
is higher than the prevalence of gonorrhea in virtually all settings.1  Therefore, stand-alone 
gonorrhea screening criteria may not be of practical use in an ED.   
 
3.2.3. Predictor Measures: Aim 1a 
The screening criteria were developed from a set of possible predictor variables in the 
following categories: demographic, sexual behaviors, partner characteristics, healthcare 
utilization, and STI health status (TABLE 3.1).  See Appendix One for a complete 
description of variables and coding schemes. 
 
3.2.4. Data Analysis: Aim 1a 
Aim 1a:  To develop and evaluate risk score algorithms, using demographic 
and behavioral characteristics, to predict current undiagnosed chlamydial and 
gonococcal infections in an Emergency Department population. 
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Analyses for Aim 1a focused on the development of predictive models for Ct infection alone 
and combined with GC infections, separately for females and males.  First, highly predictive 
(reference) models were developed for Ct infection for females and males, in addition to 
models for both infections combined for females and males.  Simpler (reduced) models that 
would be more feasible to implement in an ED setting but that remain reasonably predictive 
were also developed.  Next, we developed risk scores using the β-coefficients from our final 
predictive models.  We calculated both weighted and unweighted risk scores.  We summed 
across risk scores to create risk score algorithms.  At each step, we assessed model 
performance using sensitivities, specificities, and predetermined changes in receiver 
operating characteristic (ROC) curves.  Lastly, we validated each of our final models at two 
different risk score cut-offs using standard bootstrapping techniques (Figure 3.2). 
 
Univariable Analysis: Initial analysis involved univariable description of the outcome and 
predictor variables.  The frequencies and percentages for categorical and dichotomous 
variables were tabulated.  For continuous variables, graphical representations with reported 
means, standard deviations, and medians were developed as well as descriptions of the 
skew/kurtosis and critical percentiles.  We also assessed the frequency of missing data.  
 
Bivariable Analysis: We examined the association between each of the candidate predictors 
and each outcome (Ct only and Ct-GC combined).  Candidate variables for the predictive 
models were selected based on previous literature and the biological plausibility of a 
relationship with chlamydial and/or gonococcal infection.  Candidate variables were 
eliminated if their distributions were too narrow to be meaningfully predictive or if there was 
a substantial proportion of missing values.  Categorical predictors were assessed with chi-
square tests and continuous predictors were assessed with t-tests if their distributions were 
approximately normal.  For highly skewed variables, non-parametric tests were used. 
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Collinearity: We assessed the correlation of each predictor variable with similar variables to 
avoid collinearity and potential model convergence problems.  If both variables were 
continuous, we used correlation coefficients to assess collinearity.  Two variables with a 
correlation coefficient greater than 0.7 were considered highly correlated.  For two 
dichotomous variables, we used an odds ratio to assess collinearity and determined that the 
two variables were collinear if the odds ratio was 3 or greater.  If one variable was 
continuous and the other was categorical, we examined the magnitude of the difference in 
means in standardized units.  A difference of more than 1.5 standard deviations was 
considered a strong association.76  Variables that were highly correlated with each other 
were recoded or one of the variables was selected based on the substantive meaning and 
relationship to other variables.  
 
Number of predictors:  A predictive model’s reliability is a function of the prevalence of the 
outcome in the study population, the total study population, the number of fitted variables in 
the model, and how well the variables have been measured.  To estimate the number of 
predictors available for modeling, we used the following formula: (3*n1*n2)/10N, where 
n1= the number of persons with the outcome, n2= the number of persons without the 
outcome, and N= total number of observations.77  The estimated highest numbers of 
predictor variables that can be included in any single model are shown in Table 3.2. 
 
Variable selection for full model: For each of our four models, we used unconditional 
multiple logistic regression to assess the relationship of the predictor variables to the STI 
outcomes.  The statistical significance of the chi-square and t-test from the bivariable 
analysis, in addition to the substantive meaning of each predictor, guided selection of 
variables which were entered into the full model.  For those continuous variables that 
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violated the assumption of linearity or were better represented categorically, we developed 
categories using cut-points from previous literature, critical percentiles, or based on the 
distribution of the data.  We used a high alpha (p<0.20) to guide inclusion into the 
multivariable model to avoid exclusion of important variables that might be excluded if only 
bivariable analyses were used.78  This process ensured that only variables with minimal 
relationship to the outcome were excluded.  We considered these models to be the 
reference models given that they have the greatest predictive power. 
 
Variable selection for reduced model:  Although the full models have greater predictive 
power, they may be too complicated to be useful in a busy ED setting.  Therefore, we 
developed simpler reduced models using the same set of predictors as the full models.  All 
continuous variables were categorized and modeling proceeded in a backward elimination 
process using a lower alpha (p < 0.10) to eliminate predictors with weak predictive power.  
Changes in the area under the ROC curve were examined to assess the impact of removing 
each variable from the model and to ensure that the overall predictive accuracy was not 
significantly reduced.  We also used likelihood ratio tests to evaluate the effect of collapsing 
across categories of predictor variables. 
 
Model fit: We evaluated the full and reduced models with standard post-regression 
techniques to determine the effectiveness of the model in predicting the STI outcomes.  We 
assessed the goodness-of-fit of the models by calculating summary measures of the 
distance between the observed and predicted values using the Pearson residual and the 
deviance residual.  We concluded that all of the covariate patterns were well served by the 
model if none of the Pearson residuals were greater than 1.79  Before accepting the final 
models, we performed other regression diagnostics to ensure that the model fit was 
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supported over the entire set of covariate patterns.  Overly influential observations and 
poorly fit patterns were examined using graphical representations of the residuals.   
 
Risk Score Algorithms: To develop risk score algorithms, we used the β-coefficients of each 
predictor variable from the final predictive models.  A simple unweighted risk score was 
developed by assigning a 1 to each predictor included in the final model and summing to 
provide a cumulative risk score.  We also developed a weighted additive risk score by 
assigning a weight of 2 to certain predictors based on the distribution of the β-coefficients.  
The weighted risk scores were also summed to create a cumulative risk score. 
 
Validation:  We validated our final models using standard bootstrapping techniques.  We ran 
our final models on resampled populations in an iterative manner to generate estimates of 
standard error and bias and to construct confidence intervals around the predicted 
probabilities of our final models.  We ran 1000 samples with replacement to generate our 
bootstrapped estimates.  See Appendix Two for bootstrapped estimates of the final risk 
scores using two cutoffs, an additive risk score ≥ 2 and a risk score ≥ 5. 
 
3.2.5. Data Analysis: Aim 1b 
Aim 1b:  To assess the performance of the algorithms across varying 
prevalence on infection. 
 
Aim 1b analyses focus on identifying the “optimal” screening policy for ED settings.  We 
examined the trade-off between the number of misclassification errors that would be made 
in the absence of screening [false negatives (FN)] and the number of errors that would be 
made if screening was initiated [false positives (FP)].  We used the sensitivity and specificity 
of our final risk score algorithms and examined the trade-off at two different cutoffs, an 
 
 32 
additive risk score ≥ 2 and a risk score ≥ 5, across prevalence of infection ranging from 2% 
to 14%.   
 
We used the following formula to calculate a trade-off weight: 
wFNno screen + FPno screen = wFNscreen + FPscreen  
 
where,   
# FNno screen = prevalence of infection in the ED (because sensitivity is 0% if nobody is 
screened) 
#FPno screen  = 0 
#FNscreen     = (1 - sensitivity)*prevalence  
#FPscreen     = (1 – specificity)*(1 – prevalence), and 
w        =  weight of trade-off 
 
which is solved by the equation:  
( )( )
ysensitivitprevalence
yspecificitprevalencew ∗
−−= 11    
 
See Figure 3.3 for 2x2 table of misclassification errors and Appendix Three for results of the 
trade-off calculations and corresponding graphs. 
 
3.2.6. Data Analysis: Aim 1c 
Aim 1c: To validate the performance of previously developed screening criteria 
derived in the same setting. 
 
Previous study 6 description:  Between June and November 1998, a cross-sectional study of 
patients aged 18 to 44 was conducted to determine the prevalence of Ct and GC infection 
and assess risk factors for infection.  Patients seeking medical treatment at the Johns 
Hopkins Adult ED were included.  Psychiatric and critically ill patients were excluded in 
addition to university students, hospital employees, and patients served in common 
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treatment areas where confidentiality could not be maintained.  A convenience sample of 
700 patients completed a standardized questionnaire and provided urine specimens for 
detection of Ct and GC using LCR.  
 
Previous models.  Analyses for Aim 1c focused on the validation of previously developed 
screening criteria which were derived in the same ED setting.  Authors of the study 
conducted in 1998 analyzed four separate models estimating predictors for either chlamydial 
or gonococcal infection.6  The four models were: 
 
1. Model I: Among 18 to 44 year olds, predictive risk factors were age less than or 
equal to 31 and a new sex partner in the past 90 days. 
2. Model II: Among 18 to 31 year olds, predictive risk factors were history of STI, more 
than one sex partner in the past 90 days, and age less than 25. 
3. Model III: Among 18 to 31 year old females, predictive factors were a new sex 
partner in the past 90 days and having more than one sex partner in the past 90 
days. 
4. Model IV: Among 18 to 31 year old males, predictive risk factors were age less than 
25, penile discharge, and having ever been annoyed by others criticizing drinking 
habits. 
 
Because our study population was restricted to patients between the ages of 18 and 35, we 
were not able to validate model I.  We were also not able to evaluate one of the predictive 
risk factors in model IV: “being annoyed by criticism of drinking habits”, because this 
question was not asked in our ACASI screening questionnaire.  
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We validated models II and III by running the two models in our population and comparing 
the results to those reported by the authors.  Based on the cutoffs proposed by Mehta et. al., 
we used sensitivity and specificity, in addition to ROC curves, to assess the performance of 
the Mehta et. al. criteria. 
 
3.3. Research Design for Specific Aim 2 
Aim 2a: To examine the influence of two main factors of interest, healthcare 
coverage and reporting the Emergency Department as the main source for 
healthcare, on the risk of not receiving treatment or follow-up services for ED-
identified chlamydial and gonococcal infections. 
 
Aim 2b:  To describe the geospatial distribution of chlamydial and gonococcal 
infections identified in the ED. 
 
3.3.1. Rationale for Selected Outcome Measure: Aim 2a 
Few studies have assessed factors associated with the treatment and follow-up of patients 
who receive STI screening in an ED.  If the decision to incorporate Ct and GC screening into 
routine ED services is being considered, it naturally follows to evaluate the likelihood of 
patients receiving or not receiving treatment and follow-up services once infections are 
identified. 
 
3.3.2. Outcome Measures: Aim 2a 
The outcome measure for Specific Aim 2 was the infected patient’s treatment and follow-up 
status which was one of four possible outcomes: 
1) Patient returned to the GCRC for treatment and follow-up services 
2) Patient was located by DIS and reported receiving treatment elsewhere 
3) Patient was located by DIS but refused treatment and follow-up services 
4) DIS unable to locate patient 
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We evaluated the outcome as a dichotomous measure examining those who received 
treatment and follow-up services (at the GCRC or elsewhere) compared to those who did 
not receive treatment (because they refused and were not locatable). 
 
3.3.3. Main Factors of Interest: Aim 2a 
Healthcare coverage:  To evaluate healthcare coverage status, participants were asked the 
following questions: “Are you covered by any private health insurance that pays any part of 
your hospital or doctor bills?”, “Are you covered by Medicaid?”, “Are you covered by 
Medicare?”, and “Are you covered by a health maintenance organization or HMO?”  
Responses from these four questions were combined to create one healthcare coverage 
variable.  The variable was then dichotomized into “no healthcare coverage” and 
“Medicaid/Medicare/HMO/private”. 
 
Emergency Department as primary source for healthcare: To determine the status of 
participants’ primary health care seeking behaviors, participants were asked: “Where do you 
usually go to get your health care?”  Response categories included: private doctor, clinic, 
ED, HMO, and no usual place.  The variable was evaluated as a dichotomous measure with 
“ED as primary source” and “non-ED as primary source” as the categories for this analysis. 
 
3.3.4. Other factors of interest:  Aim 2a 
We examined additional factors of interest as potential effect measure modifiers and 
confounders.  These factors included:  gender, age, race/ethnicity, marital status, education, 
antibiotic use in the past three months, previous Ct/GC diagnosis, having a sexual partner 
diagnosed with an STI in the past two years, and travel distance from self-reported 
residential address and the emergency department. 
 
 
 36 
3.3.5. Data analysis: Aim 2a 
Aim 2a: To examine the influence of two main factors of interest, healthcare 
coverage and reporting the Emergency Department as the main source for 
healthcare, on the risk of not receiving treatment or follow-up services for ED-
identified chlamydial and gonococcal infections. 
 
 
Analyses for Aim 2a focused on evaluating the association between two main factors of 
interest, healthcare coverage and reporting the ED as a primary source for healthcare, and 
the likelihood of not receiving treatment and follow-up services for ED-identified chlamydial 
or gonococcal infections. 
 
Univariable Analysis:  Initial analysis involved univariable description of the outcome, the 
main factors of interest, and other variables of interest.  The frequencies and percentages of 
categorical and dichotomous variables were tabulated.  For continuous variables, graphical 
representations with reported means, standard deviations, and medians were developed as 
well as descriptions of the skew/kurtosis and critical percentiles.  We also assessed the 
frequency of missing data.  For variables with more than 5% missing data, we determined if 
the data was missing at random.  If data were not missing at random, we performed simple 
sensitivity analysis to establish the bounds of bias introduced by the missing data.  
 
Bivariable Analysis: We examined the association between each variable of interest and the 
outcome, in addition to examining the associations with the main factors of interest.  
Categorical variables were assessed with chi-square tests and continuous variables were 
assessed with t-tests if their distributions were normal.  We used non-parametric tests for 
highly skewed continuous variables. 
 
Multivariable Analysis:  We used generalized linear models with log link and binomial error 
distribution to estimate the risk of not receiving treatment and follow-up services among our 
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cohort of infected individuals over a specified time interval.80  The interval was determined 
based on the time between Ct-GC screening in the ED and participants’ return to the GCRC 
or the last date of DIS contact.  We constructed two separate models.  Our first model 
evaluated the influence of healthcare coverage on the risk of not receiving treatment and 
follow-up services for an ED-identified infection.  Our second model evaluated the influence 
of reporting the ED as a primary source for healthcare on the risk of not receiving treatment 
and follow-up services.  As an additional step, we used a modified Poisson regression 
without an offset to estimate risk ratios for the main associations to ensure that results were 
comparable to estimates from the generalized linear models.81 
 
Effect Measure Modification:  To identify variables for which the association between each 
of the main factors of interest and the outcome varied between different levels of potential 
effect measure modifiers, we calculated stratum-specific risk ratios of the main association 
across each category for every variable of interest.  To determine if there was effect 
measure modification by a specific variable, we compared stratum-specific risk ratios to 
each other.  Because there is not an appropriate statistical significance test associated with 
binomial regression or Poisson regression, non-overlapping confidence intervals were used 
as the criterion for statistical significance.  We accounted for any effect measure modifiers 
by including interaction terms with the main factor of interest in our models. 
  
Confounding:  Variables that were not identified as effect measure modifiers were assessed 
as potential confounders.  We evaluated confounding by comparing the stratum-specific 
estimates to the crude estimate of the main association.  If the stratum-specific estimates 
were similar to each other, but different from the crude estimate, we examined the adjusted 
Mantel Haenszel estimate.  We calculated the change in estimate resulting from removing 
the potential confounder from the model during the model building process using the 
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following formula: 100*(adjusted – crude)/crude.  A change in estimate of 10% or more was 
considered indicative of confounding.  For effect measure modifiers, we examined potential 
confounding within each strata of the effect measure modifier(s).   
 
Model Building:  To determine an unbiased estimate of the association between each of the 
main factors of interest, healthcare coverage and reporting the ED as the primary source for 
healthcare, and not receiving treatment and follow-up services for an ED-identified infection 
we used a backwards elimination process.  Each of the starting models consisted of the 
main factor of interest, interaction terms for variables identified as potential effect measure 
modifiers, and other measured variables identified as potential confounders.  The first step 
in the backwards elimination process was to remove from the starting model any interaction 
terms included to account for potential effect measure modifiers and to compare the 
resulting models using a likelihood ratio test.  The next step was to assess each covariate 
for its potential to confound the main association.  The covariate with the largest Wald p-
value was removed from the model and the main association estimate from the full model 
was compared to the reduced model.  If the change in the estimate was less than 10% that 
covariate was not considered to be a confounder and was dropped from the model.  The 
process was repeated for each covariate.  For covariates that were included in the model as 
indicator variables, the set of variables was assessed as a group because indicator coding 
is dependent on the category definitions.  The group of indicator variables was also 
assessed using the Wald p-value.     
 
The final model consists of the main factor of interest, significant product interaction terms 
for effect measure modifiers, and all covariates that confound the main association.  
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3.3.6. Data analysis: Aim 2b 
Aim 2b:  To describe the geospatial distribution of chlamydial and gonococcal 
infections identified in the ED. 
 
We defined a case as a Baltimore City resident with a positive LCR/PCR result from a 
specimen collected during the ED screening phase of the study.  We used Environmental 
Systems Research Institute’s (ESRI) StreetMap 2006 to geocode self-reported residential 
addresses to physical locations using ArcGIS software (ESRI, Redlands, CA).  The 
geocoded addresses were then projected into North American Datum 1983 State Plane 
Meters and linear travel distance to the emergency department was calculated by spatially 
joining the physical address of the ED to the geocoded addresses.  We evaluated the 
influence of travel distance on patients’ likelihood of not receiving treatment or follow-up 
services, in addition to evaluating travel distance as a potential confounder in our models of 
the main associations.  Graphically, we created a count map of infections within each 
census block group.  We also created maps comparing the geospatial distributions of 
treated and untreated infections. 
  
Bivariable analysis:  To evaluate the association between travel distance and the risk of not 
receiving treatment or follow-up services for an ED-identified infection, we used the non-
parametric Wilcoxon rank-sum test due to highly skewed nature of the travel distance data.  
Among patients who received treatment and follow-up services, the median travel distance 
to the ED was 2.66 kilometers compared to a mean travel distance of 4.00 kilometers with a 
standard deviation of 4.15 kilometers.  Among patients who did not receive treatment and 
follow-up services for their ED-identified infection, the median travel distance was 2.89 
kilometers compared to a mean of 5.32 kilometers with a standard deviation of 8.66 
kilometers. 
 
 40 
TABLE 3.1: Individual-level factors evaluated as screening criteria 
 
Demographics 
 
Age  
Race/ethnicity 
Current marital status 
Educational attainment 
 
 
Sexual Behaviors 
 
Condom use during last 5 sex acts 
Number of partners during past 2 years 
Number of partners during past 3 months 
Time of last new sex partner 
 
 
Partner Characteristics 
 
Partner has concurrent partners 
Partner diagnosed with STI/HIV infection 
 
 
Healthcare Utilization 
 
Insurance status  
Primary source for health care 
Reason for ED visit 
Recent antibiotic use 
 
 
STI Health Status 
 
History of self-reported Ct/GC 
Genitourinary symptoms suggestive of STI 
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TABLE 3.2: Estimated number of variables available for logistic regression (N=6,000) 
 
Estimated 
Prevalence Number Positive (3*n1*n2) 
Number of 
Variables 
1.0% 60 1069200 18 
2.0% 120 2116800 35 
3.0% 180 3142800 52 
4.0% 240 4147200 69 
5.0% 300 5130000 86 
6.0% 360 6091200 102 
7.0% 420 7030800 117 
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FIGURE 3.1: Flow of study participants 
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FIGURE 3.2:  Analysis plan for Aim1a 
 
 
 
 44 
 
FIGURE 3.3:  Misclassification errors 
 
 
  
 
CHAPTER FOUR: EVALUATION OF RISK SCORE ALGORITHMS FOR DETECTION OF 
CHLAMYDIAL AND GONOCOCCAL INFECTIONS IN AN EMERGENCY DEPARTMENT 
SETTING 
 
 
4.1. Abstract 
Objectives:  To develop and evaluate screening algorithms to predict current chlamydial and 
gonococcal infections in emergency department (ED) settings and assess their performance 
across varying prevalence levels.  
 
Methods:  Between 2002 and 2005, adult patients aged 18 to 35 years attending an urban 
ED were screened for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) and 
completed a brief demographic and behavioral questionnaire.  Using multiple unconditional 
logistic regressions, we developed four separate predictive models and applicable clinical 
risk scores to screen for infection.  Separately for females and males, we developed models 
for Ct and GC infections combined and for Ct infection alone.  We used the sensitivities and 
specificities of the clinical risk scores at different cutoffs to examine performance of the 
algorithms across varying prevalence of infection.   
 
Results:  Among 5,537 patients successfully screened for Ct and GC, the overall prevalence 
of infection was 9.6%.  Age was the strongest predictor of infection.  Adjusting for other 
predictors, the prevalence odds ratio (POR) was 2.2 (95% CI: 1.7, 2.8) for Ct and GC 
combined and 2.9 (95% CI: 2.1, 4.1) for Ct alone comparing females 25 years and younger 
to females older than 25.  Among males, the association was stronger with an adjusted POR 
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of 3.3 (95% CI: 2.3, 4.7) for Ct and GC combined and 3.2 (95% CI: 2.1, 4.7) for Ct infection 
alone.   
 
Conclusions:  If the decision to incorporate Ct and GC screening into routine ED care is 
made, age alone appears to be a sufficient screening criterion.   
 
4.2. Introduction 
In 2005, approximately one million chlamydial infections and 350,000 gonococcal infections 
were reported to the Centers for Disease Control and Prevention (CDC).1  Importantly, these 
estimates only reflect the burden of reported infections.  Assuming that not all infections are 
reported or even diagnosed, the true burden of infection increases to an estimated 2.8 
million Americans infected with Chlamydia trachomatis (Ct) and 718,000 infected with 
Neisseria gonorrhoeae (GC) each year.11 
 
The majority of Ct and many GC infections do not produce symptoms.  Relying on clinic 
visits for identification and treatment of infected individuals thus has limited effectiveness.3  
Without vigorous public health interventions, the majority of asymptomatic infections will 
remain untreated, allowing for persistent infection, potential transmission to sexual partners 
and, in some individuals, progression to serious complications.  In addition, inflammatory 
STIs such as chlamydial and gonococcal infections may increase susceptibility to and 
transmission of the human immunodeficiency virus (HIV).18-22  
 
In recent years, Emergency Departments (EDs) have been proposed as promising venues 
for providing screening interventions.4  EDs often serve as primary care sites for persons 
who do not have regular access to healthcare, typically inner-city and difficult-to-reach 
patient populations.5  Many of those at highest risk for STIs do not have access to regular 
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healthcare and, therefore, may be accessible through EDs.6, 82   A handful of studies 
demonstrating the acceptability and feasibility of Ct and GC screening in EDs have detected 
prevalences ranging from 8% to 11% for Ct infection and 2% to 9% for GC infection.6, 40, 65, 83   
These prevalences are similar to those detected in other more traditional clinical venues 
where STI testing services are routine.84-86  
 
To provide a more accurate understanding of the potential utility of screening for Ct and GC 
in an ED setting, we developed and evaluated ED-specific clinical risk scores for use as 
screening criteria.  We also evaluated the criteria’s performance across varying levels of 
prevalence to provide a starting point for EDs considering incorporating Ct and GC 
screening into routine care.  Using data from a study of patients attending an urban ED, we 
assessed the effectiveness of screening for undiagnosed Ct and GC infection in this setting. 
 
4.3. Methods 
4.3.1. Study Design 
This cross-sectional analysis is part of a larger study of patients presenting at The Johns 
Hopkins Hospitals Adult ED in Baltimore, MD between November 2002 and February 2005.  
Patients were eligible to participate in the screening phase of the study if they were between 
the ages of 18 and 35 years, English-speaking, and sexually active in the past 90 days.  
Patients that were critically ill or presenting to the ED for acute psychiatric or STI-related 
symptoms, as well as Johns Hopkins employees and students, were excluded.  Participants 
completed a brief demographic and behavioral audio computer-assisted self-interview 
(ACASI) questionnaire and provided specimens for nucleic acid amplification testing (NAAT) 
for Ct and GC.  Contact information was collected from all patients who provided specimens 
to locate and follow-up those who tested positive for either infection.  Participants received a 
$10 food coupon for their participation.  Further details of the study protocol are described 
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elsewhere.87  Analyses presented in this paper focus on participants who were successfully 
screened in the ED and who completed the ACASI questionnaire. 
 
Written informed consent was obtained from all study participants.  The Institutional Review 
Boards of RTI International, Johns Hopkins Hospitals (JHH), and the University of North 
Carolina at Chapel Hill (UNC) approved the study protocol.  In compliance with Maryland 
state laws, patients identified with Ct or GC infection were reported to the Baltimore City 
Health Department. 
 
4.3.2. Specimen Collection and Testing 
From the time of study initiation in November 2002 until June 2003, a ligase chain reaction 
(LCR) assay (Abbott Laboratories, North Chicago, IL) was used to test for Ct and GC from 
urine specimens collected from all participants.  In addition to the LCR assay performed on 
the urine specimens, a polymerase chain reaction (PCR) assay (Roche Diagnostic Systems, 
Indianapolis, IN) was used to test for both organisms from self-collected vaginal swabs 
provided by female participants.  All specimens collected in the JHH ED were stored at 
approximately 4°C until being shipped for processing and testing at the UNC Microbiology 
Laboratory. 
 
Abbott Laboratories discontinued production of the LCR GC/Ct testing kits in 2003.75  As a 
result, all specimens collected after July 2003 were tested by PCR only.  Because GC 
detection in female urine specimens using PCR is not approved by the Food and Drug 
Administration (FDA), the study discontinued collecting urine specimens from female 
participants.  Study quality and participant care were not affected by this protocol change.  
The sensitivities and specificities of the LCR and PCR are similar.41, 88, 89  
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4.3.3. Data Analysis and Statistical Methods 
All analyses were conducted using Stata version 8.0 (StataCorp, College Station, TX).  We 
developed four separate predictive models and clinical risk scores to screen for Ct and GC 
infections in the ED.  The four outcomes of the predictive models are: 1) Ct and GC infection 
combined among females, 2) Ct infection only among females, 3) Ct and GC infection 
combined among males, and 4) Ct infection only among males.  We chose to evaluate these 
four models separately for two reasons.  First, the clinical consequences of untreated 
infections between females and males are inherently different which may require gender-
specific screening criteria.  Second, screening for GC is generally not recommended in 
settings where Ct screening is not already in place given the higher prevalence of Ct 
infection in virtually all settings.  Therefore, stand-alone GC screening criteria are not of 
practical use in an ED.   
 
The set of possible predictor variables included demographics (age, education, and current 
marital status), sexual behaviors (condom use, number of sex partners, and time of last new 
sex partner), partner characteristics (sexual contact with an STI-infected person and sexual 
contact with a person who has concurrent partners), healthcare utilization (current insurance 
status, primary healthcare seeking behaviors, reason for ED visit, and antibiotic use), and 
STI health status (history of Ct/GC infection and genitourinary symptoms which could be 
indicative of an STI). 
 
We examined the crude association between each predictor variable and the four possible 
outcomes using unadjusted prevalence odds ratios and their associated 95% confidence 
intervals.  Variables for which p<0.20 were selected for evaluation in multiple unconditional 
logistic regression.77  The first model, or ‘reference model’, included all predictors identified 
during the bivariable analyses.  Variables were removed from the reference model based on 
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the Wald X2 p-value in the unconditional logistic model, beginning with the variable with the 
highest p-value.90  We used receiver operating characteristic (ROC) curves and likelihood 
ratio tests to assess model performance during the model building process.  Changes in the 
area under the ROC curve were used to assess variations in model performance due to 
collapsing across categories or removing variables.  In addition, likelihood ratio tests were 
used to evaluate significant changes in model performance due to removal of variables.  
The modeling procedures were limited to those persons with complete data for all variables 
in the reference model.  The final model, or ‘reduced model’, includes all predictors for which 
p<0.05.   
 
We created applicable clinical risk scores for each of the four outcomes using the β-
coefficients corresponding to each predictor in the reduced model to compute weighted risk 
scores.  We assigned different weights to each predictor based on the distribution of the β-
coefficients.  For the female Ct and GC combined risk score, we assigned a weight of 1 to 
predictors with β <0.5 and a weight of 2 to predictors with β >=0.5.  For the other three 
models, we assigned a weight of 1 to predictors with β <1.0 and a weight of 2 to predictors 
with β >=1.0.   These individual weights were summed to create an overall clinical risk score 
for each of the four outcomes for each patient.  We used 1,000 bootstrap samples with 
replacement to validate our model and risk score performance.77 
 
To identify an ‘optimal’ screening policy for ED settings, we examined the trade-off between 
the number of misclassification errors that would be made in the absence of screening and 
the number of errors that would be made if screening was initiated.  We focused on false 
negatives (FN) and false positives (FP), or the ‘errors’, because routine Ct and GC 
screening is not offered in most EDs.  Therefore, we are examining the impact of 
misclassification errors on the patient and on the ED if screening was to be initiated.  We 
 
 51 
considered a FN to be a patient who is infected but whose infection remains undetected 
because that patient is not screened and a FP to be a patient who is not infected but is 
screened based on the selected screening criteria.  
 
We used the following formula to calculate a trade-off weight:   
wFNno screen = wFNscreen + FPscreen  where,   
 
FNno screen = false negatives based on not screening which is equivalent to the 
prevalence of infection in the ED (because sensitivity is 0%) 
 
FNscreen    = false negatives based on screening which is  
(1 - sensitivity)*prevalence  
 
FPscreen    = false positives based on screening which is  
(1 – specificity)*(1 – prevalence) 
 
w     =  weight of trade-off 
 
which is solved by the equation:  
( )( )
ysensitivitprevalence
yspecificitprevalencew ∗
−−= 11    
 
We compared the trade-off weight for two separate risk score cutpoints, at ≥ 2 and at ≥ 5, 
across prevalence of infection ranging from 2% to 14%.  We used the sensitivity and 
specificity of the risk scores at each cut-off to calculate the optimal trade-off. 
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As a final step in our analyses, we assessed the performance of previously developed 
criteria derived in the same ED setting6 to predict the likelihood of infection in our ED 
sample.  The previously developed criteria proposed using any one of the following factors 
to screen for Ct and GC infection among 18 to 31 year olds: previous history of STI, more 
than one partner in the past three months, or age less than 25. Restricting to females, the 
previously proposed screening criteria were: previous history of STI or having a new sexual 
partner in the past 90 days.  To provide a comparable sample, we limited this analysis to 
patients aged 18 to 31 and calculated a risk score based on screening using any one of 
these factors.  
 
4.4. Results  
4.4.1. Study Population 
A total of 7,532 eligible patients were approached to participate, of whom 6,195 patients 
consented to enroll (82% response rate).  Of the consenting participants, 494 patients (8% 
of those consenting) did not complete the ACASI questionnaire and 164 patients (3%) did 
not provide a specimen or provided an unusable specimen (e.g. specimen leaked during 
transport).  Only participants who completed the ACASI questionnaire during their ED visit 
and provided a urine or self-collected vaginal swab specimen with a valid test result are 
included in these analyses (n=5,537; 74%).   
 
 
4.4.2. Characteristics of the Study Population 
Overall, 9.6% of participants screened in the ED tested positive for Ct and GC combined 
and 7.1% tested positive for Ct only (Table 4.1).  Most participants screened in the ED were 
African-American (82.4%) and slightly more than half (55.6%) were female.  The average 
age was 25.9 ± 5.2 years.  Almost 30% of participants reported having more than one 
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sexual partner in the past three months, while 16% reported that their partners in the past 
three months had other sexual partners.  Only 22% of participants reported using condoms 
consistently during the last five sex acts.  Roughly 40% reported having a prior Ct/GC 
infection.  Almost one-fourth of the participants reported using the ED as their primary 
source for healthcare while 57% reported having some type of health insurance. 
 
4.4.3. Bivariable Analyses 
In this ED population, age was the predictor most strongly associated with all four outcomes.  
Among females, the odds of infection for participants 25 years and younger was 2.4 (95% 
CI: 1.9, 3.0) times as high for Ct and GC infections combined and 3.4 (95% CI: 2.5, 4.7) 
times as high for Ct infection alone compared to females older than 25 years.  Among 
males, the odds of infection was nearly four times as high for participants who were 25 
years and younger compared to older males for both outcomes (Ct and GC combined OR: 
3.9, 95% CI: 2.8, 5.4 and Ct alone OR: 3.9, 95% CI: 2.7, 5.7).  
 
4.4.4. Predictive Models for Females 
Among females, younger age, not being married, having a high school education or less, 
having a new sexual partner within the past two years, not reporting the ED as the primary 
source for healthcare, not using antibiotics in the past month, reporting a prior Ct/GC 
infection in the past year, experiencing dysuria or discharge in the past three months, and 
ever experiencing any pain during intercourse or bleeding between menstrual cycles were 
significant predictors of Ct and GC infection combined in the reference model (Table 4.2).  
Demographic predictors of Ct alone were similar to predictors of Ct and GC infection 
combined, whereas predictors relating to sexual behaviors and genitourinary symptoms 
differed.  In the reference model for Ct alone, the number of sexual partners, rather than the 
timing of the last new sexual partner, was a significant predictor and experiencing painful 
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intercourse and bleeding between menstrual cycles was not.  We used the area under the 
ROC curve as a measure of model performance.  The ROC areas for the female reference 
models were 0.6765 for Ct and GC combined and 0.7192 for Ct alone. 
 
After removing variables that were less strongly associated with infection status and 
collapsing categories to create a more parsimonious model, the reduced model to predict 
the likelihood of infection with Ct and GC combined included: age less than 25 years, high 
school education or less, having a new sexual partner within the past two years, and 
experiencing dysuria or discharge in the past three months (Table 4.3).  Predictors for Ct 
alone were similar with the addition of not reporting the ED as the primary source for 
healthcare.  There was some loss in model performance resulting in ROC areas of 0.6484 
and 0.6944 for the reduced Ct and GC combined and Ct alone models, respectively.  
 
4.4.5. Predictive Models for Males 
Among males, younger age, not being married, having three or more sexual partners in the 
past three months, having a new sexual partner within the past two years, not having health 
coverage, no antibiotic use in the past month, and experiencing dysuria or discharge in the 
past three months were significant predictors of Ct and GC infection combined in the 
reference model (Table 4.2).  Predictors for Ct alone were similar with the addition of 
education level and knowing or suspecting that the current sexual partner had other sexual 
partners.  For the male reference models, the ROC area was 0.7483 for Ct and GC 
combined and 0.7447 for Ct alone. 
 
The reduced model to predict the likelihood of Ct and GC infection combined included: age 
less than 25 years, being single, having a new sexual partner within the past two years, and 
experiencing dysuria or discharge in the past three months (Table 4.3).  Predictors for Ct 
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alone were similar.  The ROC areas for the reduced Ct and GC combined and Ct alone 
models were 0.7193 and 0.7145, respectively. 
 
4.4.6. Clinical Risk Score Algorithms 
We developed weighted clinical risk scores using the predictors from the final reduced 
models.  For the Ct and GC combined female model, age less than 25 and having a new 
sexual partner in the past two years were weighted with a score of 2; and having at least a 
high school education and experiencing dysuria or discharge in the past three months were 
weighted with a score of 1.  These individual risk scores were summed to create an overall 
clinical risk score algorithm for Ct and GC combined with a range of scores between 0 and 
6.  For example, a 20 year old patient reporting she had experienced dysuria or discharge in 
the past three months would be assigned a risk score of 3.  For the Ct only model, age less 
than 25 was assigned a score of 2, and the other four predictors from the final model were 
weighted with a score of 1 (Table 4.4).  
 
The clinical risk score algorithms were similar for Ct and GC combined and Ct alone for 
males.  For both models, age less than 25 was weighted with a score of 2; and being single, 
having a new sexual partner in the past two years, not using antibiotics in the past month, 
and experiencing dysuria or discharge in the past three months were weighted with a score 
of 1. 
 
4.4.7. Model Performance Across Varying Prevalence 
We examined the trade-off between missing an infected patient by not screening and 
screening patients who are not infected to assess how well our risk scores would predict 
infections and identify the optimal screening policy for an ED setting.  We examined the 
trade-offs to screening based upon a risk score ≥ 5 and a risk score ≥ 2 across varying 
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infection prevalence.  The two cut-points represent screening using highly sensitive criteria 
(risk score ≥2) and screening using highly specific criteria (risk score ≥5).  Because the 
performance of any screening criteria is influenced by the prevalence of infection or disease, 
we evaluated the criteria across varying prevalence.  For example, to justify screening for Ct 
and GC among females in an ED with a prevalence of 11% (the prevalence in our sample) a 
FN would have to be roughly 5 times “worse” than a FP if every patient with a risk score ≥5 
was screened and 8 times worse if every patient with a score ≥ 2 was screened (Figure 4.1).  
If we applied the same screening criteria in an ED with a lower prevalence of 2%, the trade-
off between FN and FP would have to be much higher to justify screening, at a weight of 29 
times “worse” using a risk score of ≥ 5 and 44 times worse using a score ≥ 2.  For all four 
models, the weight of FN to FP decreases as the prevalence increases. 
 
4.4.8. Validation of Previously Developed Criteria 
To assess the performance of criteria previously developed in the same ED setting,6 we 
included the previously proposed predictors in a logistic regression model which we ran in 
our study sample.  Screening using any one of the previously proposed criteria in our 
sample resulted in models with lower sensitivity, 92% compared to 93% for the first model 
and 69% compared to 78% for the second model, and higher specificity, 21% versus 12% 
for the first model and 42% versus 38% for the second model (Table 4.5).  
 
4.5. Discussion 
We assessed the effectiveness of screening for Ct and GC in a busy urban adult emergency 
department.  Using demographic and behavioral data, we developed four separate ED-
specific risk score algorithms to predict current undiagnosed infections.  While data suggest 
that EDs may represent high-yield screening venues, consideration must be given to the 
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costs of implementing and sustaining routine screening in emergency departments in the 
absence of research studies.   
 
We detected levels of infection within the range of prevalences reported in previous studies 
conducted in ED settings.6, 40, 56, 83   While screening in the ED appears to detect levels of 
infection comparable to other high risk settings, several operational hurdles exist that make 
implementing and sustaining routine Ct and GC screening in EDs a significant public health 
undertaking.  The most significant obstacle is the shortage of human resources required to 
provide the necessary follow-up and treatment for patients identified as infected.  This may 
be offset in the future, were point of care Ct and GC assays to gain greater acceptance.  
However, other barriers would remain as have been seen with efforts to implement routine 
point of care HIV testing in EDs.91-93  
 
If the decision to implement routine Ct and GC screening in an ED is made, our study 
provides ED-specific screening criteria which perform reasonably well for predicting 
infection.  Our analyses confirm that age is the strongest predictor of infection.  For all four 
risk score algorithms, screening using age alone is equivalent to screening using a risk 
score ≥ 2 (out of a maximum of 6).  Given the small increment in predictive power when 
other screening criteria are included, age alone appears to be a sufficient screening criterion 
in an ED setting.  We did not include patient’s racial and ethnic background during the 
development of the risk score algorithms due to the potential sensitivity of proposing 
screening criteria based on an individual’s racial and ethnic background.  However, we did 
evaluate our models including race in the development process to evaluate its impact and 
there was no detectable difference given the high uniformity in this ED setting 
(approximately 80% of our population was African American).   
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Similar to previous ED studies, we relied on dedicated study personnel and funding to 
conduct all screening activities.  Given this, our research does not provide an accurate 
representation of the effectiveness of fully integrating STI screening into routine ED 
practices.  However, our analyses provide a starting point for EDs considering introducing Ct 
and GC screening into their routine services by presenting crude estimates of the trade-off 
between missed infections (FN) and unnecessary screens (FP) across varying prevalence of 
infection.  We chose to present our analyses within a framework that conceptualizes the 
trade-offs necessary to begin implementing routine screening in an ED without associating 
actual costs, but instead using the weight of misclassification errors.  
 
As noted, the added burden of time involved in routine screening may be overwhelming to 
already over-burdened ED staff.  Additionally, the economic cost of purchasing and testing 
the assays themselves, outside the context of a research study, must be absorbed by either 
the ED or the local public health infrastructure.  As with any screening program, budgetary 
constraints will ultimately be the deciding factor in whether or not to implement Ct and GC 
screening in resource-limited ED settings. 
 
Routine screening rates are relatively low even in settings where resources are available.  
Analysis of the 1999-2000 Health Plan Employer Data and Information Set (HEDIS) 
determined that despite increases in screening by both commercial and Medicaid health 
insurance plans, screening rates are low.31  In 2001, among sexually active females aged 16 
to 26 enrolled in commercial health insurance plans, 26% were screened for chlamydial 
infection while 38% of 16 to 26 year olds in Medicaid plans were screened.  These 
proportions represent increases of 6% and 10%, respectively, over the percentages 
screened in 1999.  Despite the increase, these percentages fall well below the CDC’s 
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recommendation to routinely screen all sexually active females younger than 26 years of 
age. 
 
Despite the operational and financial obstacles involved in routine screening, the cost of 
missed infections can be substantial.  Undetected infections can cause serious clinical 
sequelae.  In women, untreated Ct and GC infections can ascend from the vagina or cervix 
into the upper genital tract and cause infections in the endometrium, fallopian tubes, and 
contiguous structures resulting in pelvic inflammatory disease (PID).  The tubal scarring 
associated with PID can lead to complications such as infertility, ectopic pregnancies, and 
chronic pelvic pain.94  If these infections are not treated adequately, 20% to 40% of Ct 
infected women and 10% to 40% of GC infected women may develop PID.11   With Ct 
infections, undertreatment can also lead to recurrent or persistent infections.60-62  
Furthermore, infants born to infected mothers are susceptible to conjunctivitis and neonatal 
pneumonia; and in men, untreated chlamydial and gonococcal infections increase the risk of 
urethritis, prostatitis, and epididymitis.10   Additionally, undetected and untreated infections 
may be transmitted to sexual partners. 
 
Our findings suggest that, across varying prevalence of infection, the consequences of 
undetected Ct and GC infections must outweigh the operational and economic obstacles of 
screening to justify incorporating screening programs as part of routine ED services.  
However, given that the prevalence of Ct and GC remain high despite screening efforts in 
traditional clinical settings and the significant clinical sequelae of untreated infections, ED 
screening may warrant being moved to the forefront of non-clinic STI screening programs. 
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TABLE 4.1: Population characteristics by Chlamydia trachomatis (Ct) and Neisseria 
gonorrhoeae (GC) infection status, restricted to complete cases 
 Ct and/or GC +  Ct + Only  TOTAL
 N (%)  N (%)  N (%)
Overall  534 (9.6)  391 (7.1)  5,537
    
Demographics    
Gender    
   Female 346 (11.2)  230 (7.5)  3,080 (55.6)
   Male 188 (7.7)  161 (6.6)  2,475 (44.4)
Race    
   African American 484 (10.6)  354 (7.8)  4,561 (82.4)
   Non-African American 50 (5.1)  37 (3.8)  974 (17.6)
Marital status    
   Single 458 (10.6)  344 (8.0)  4,306 (77.8)
   Married 28 (4.0)  17 (2.4)  706 (12.8)
   Divorced/Widowed/Separated 48 (9.2)  30 (5.8)  522 (9.4)
 Education    
   < High school 230 (10.8)  165 (7.8)  2,125 (38.5)
   High school 234 (10.1)  180 (7.8)  2,325 (42.1)
   > High school 70 (6.5)  46 (4.3)  1,071 (19.4)
Age 23.2 (SD 4.6)  22.8 (SD 4.3)  26.9 (SD 5.2)
   18 – 20 189 (17.7)  148 (13.9)  1,067 (19.3)
   21 – 25 204 (11.4)  154 (8.7)  1,789 (32.3)
   26 – 30 87 (6.6)  57 (4.3)  1,314 (23.7)
   31 – 35 54 (4.0)  32 (2.3)  1,367 (24.7)
Sexual Behaviors and Partner Characteristics    
Condom use    
   5 out of last 5 times 99 (8.2)  76 (6.3)  1,208 (22.0)
   < 5 out of last 5 times 432 (10.1)  313 (7.3)  4,288 (78.0)
Number of partners past 3 months    
   3 or more 111 (12.9)  88 (10.3)  860 (15.5)
   2 partners 93 (11.6)  63 (7.9)  805 (14.6)
   1 partner 265 (8.6)  192 (6.3)  3,078 (55.6)
   None 65 (8.2)  48 (6.1)  794 (14.3)
Last new partner    
   Past 3 months 207 (12.0)  148 (8.6)  1,723 (32.1)
   3 to 24 months 218 (10.9)  168 (8.4)  2,005 (37.4)
   2+ years 97 (5.9)  64 (3.9)  1,639 (30.5)
Suspect concurrent partners    
   Yes/Don’t Know 330 (11.6)  249 (8.8)  2,853 (51.8)
   No 203 (7.6)  142 (5.4)  2,660 (48.2)
Partner diagnosed with STI past 2 years    
   Yes/Don’t Know 162 (10.1)  120 (7.5)  1,600 (29.0)
   No 372 (9.5)  271 (6.9)  3,927 (71.0)
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Healthcare Utilization and STI Health Status    
Health coverage    
   No coverage 223 (9.4)  169 (7.1)  2,370 (43.0)
   Medicare/Medicaid/HMO 308 (9.8)  219 (7.0)  3,146 (57.0)
Primary source for healthcare    
   Non-Emergency Department 429 (10.0)  321 (7.5)  4,278 (77.3)
   Emergency Department 105 (8.3)  70 (5.6)  1,259 (22.7)
Antibiotic use past month    
   No 464 (10.0)  343 (7.4)  4,625 (84.0)
   Yes 68 (7.7)  48 (5.5)  881 (16.0)
Prior Ct/GC infection    
   Ct 94 (10.7)  63 (7.2)  881 (16.0)
   GC 79 (10.8)  55 (7.5)  733 (13.3)
   Ct and GC 67 (12.6)  45 (8.5)  531 (9.6)
   No 291 (8.6)  226 (6.7)  3,368 (61.1)
Females: Dysuria or discharge    
   Past 3 months 147 (13.4)  99 (9.1)  1,097 (35.9)
   No or > 3 months 197 (10.0)  130 (6.7)  1,962 (64.1)
Females: Pain during intercourse or bleeding    
   Ever 157 (12.2)  103 (8.0)  1,287 (41.7)
   Never 188 (10.5)  127 (7.1)  1,798 (58.3)
Males: Dysuria, discharge, or pain    
   Past 3 months 50 (14.2)  39 (11.1)  353 (14.7)
   No or > 3 months 134 (6.6)  118 (5.8)  2,043 (85.3)
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TABLE 4.2: Adjusted* odds ratios and associated 95 percent confidence intervals for variables included in the ‘reference’ models to 
predict undetected Ct and GC infections combined and Ct alone by gender 
  FEMALES  MALES 
  Ct and/or GC Ct only  Ct and/or GC Ct only
  (ROC=0.6765) (ROC=0.7192)  (ROC=0.7483) (ROC=0.7447)
Predictor  OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI)
Demographics   
Age  0.64 (0.49, 0.83) 0.64 (0.46, 0.88)  0.97 (0.65, 1.45) 1.14 (0.73, 1.78)
Marital status   
   Single  1.40 (0.87, 2.25) 1.65 (0.87, 3.13)  1.41 (0.82, 2.41) 1.46 (0.81, 2.62)
   Divorced/Widowed/Separated  1.85 (1.03, 3.33) 1.86 (0.85, 4.11)  1.0 (ref) 1.0 (ref)
   Married  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
Education   
   ≤ High school  1.49 (1.08, 2.07) 1.82 (1.19, 2.79)  NIM** 1.25 (0.73, 2.13)
   > High school  1.0 (ref) 1.0 (ref)  1.0 (ref)
Sexual Behaviors and Partner Characteristics  
Number of partners past 3 months  
   2 or more partners  NIM 1.20 (0.86, 1.65)  1.36 (0.98, 1.89) 1.25 (0.87, 1.80)
   1 or no partners  1.0 (ref)  1.0 (ref) 1.0 (ref)
Last new partner   
   Within past 2 years  1.64 (1.24, 2.17) 1.59 (1.11, 2.28)  1.74 (1.06, 2.85) 1.67 (0.97, 2.88)
   Longer than 2 years  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
Suspect concurrent partners   
   Yes/Don’t know  NIM 1.16 (0.85, 1.58)  NIM 1.23 (0.83, 1.82)
   No  1.0 (ref)  1.0 (ref)
Healthcare Utilization and STI Health Status  
Healthcare coverage   
   No coverage  NIM  NIM  1.41 (1.01, 1.97) 1.33 (0.93, 1.91)
   Medicare/Medicaid/HMO   1.0 (ref) 1.0 (ref)
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Primary source for healthcare   
   Non-Emergency Department  1.37 (0.96, 1.94) 2.01 (1.25, 3.25)  NIM NIM
   Emergency Department  1.0 (ref) 1.0 (ref)  
Antibiotic use     
   Not in past month  1.33 (0.97, 1.85) 1.34 (0.90, 2.00)  1.84 (1.05, 3.22) 1.95 (1.05, 3.61)
   Past month  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
Prior Ct/GC diagnosis   
   Within past year   1.18 (0.93, 1.51) 1.36 (0.92, 2.01)  NIM NIM
   No or > 1 year  1.0 (ref) 1.0 (ref)  
Dysuria or discharge   
  Past 3 months  1.32 (1.03, 1.70) 1.35 (1.01, 1.81)  2.37 (1.64, 3.41) 1.97 (1.32, 2.95)
  No or > 3 months  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
Pain during intercourse or bleeding  
  Ever  1.15 (0.90, 1.48) NIM  NIM NIM
  Never  1.0 (ref)  
NOTES: * adjusted for all other variable in the model, ** NIM – not in model 
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TABLE 4.3: Adjusted* odds ratios and associated 95 percent confidence intervals for variables included in the ‘reduced’ models to 
predict undetected Ct and GC infections combined and Ct alone, by gender 
  FEMALES  MALES 
  Ct and/or GC Ct only  Ct and/or GC Ct only
  (ROC=0.6484) (ROC=0.6944)  (ROC=0.7193) (ROC=0.7145)
Predictor  OR (95% CI) OR (95% CI)  OR (95% CI) OR (95% CI)
Demographics    
Age    
   ≤ 25 years  2.18 (1.70, 2.81) 2.94 (2.12, 4.09)  3.25 (2.25, 4.69) 3.15 (2.13, 4.68)
   > 25 years  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
Marital status    
   Single  NIM** NIM  1.72 (1.01, 2.92) 1.79 (1.00, 3.18)
   Married/Divorced/Widowed/Separated   1.0 (ref) 1.0 (ref)
Education    
   ≤ High school  1.60 (1.16, 2.21) 2.05 (1.35, 3.12)  NIM NIM
   > High school  1.0 (ref) 1.0 (ref)  
Sexual Behaviors    
Last new partner    
   Within past 2 years  1.82 (1.39, 2.40) 1.97 (1.41, 2.77)  2.06 (1.28, 3.31) 2.04 (1.22, 3.40)
   Longer than 2 years  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
Healthcare Utilization and STI Health Status   
Primary source for healthcare    
   Non-Emergency Department  NIM 2.03 (1.26, 3.27)  NIM NIM
   Emergency Department  1.0 (ref)  
Antibiotic use      
   Not in past month  NIM NIM  1.88 (1.08, 3.30) 1.97 (1.06, 3.64)
   Past month    1.0 (ref) 1.0 (ref)
Dysuria or discharge    
  Past 3 months  1.34 (1.06, 1.70) 1.38 (1.04, 1.83)  2.38 (1.66, 3.42) 2.06 (1.39, 3.06)
  No or > 3 months  1.0 (ref) 1.0 (ref)  1.0 (ref) 1.0 (ref)
NOTES: * adjusted for all other variables in the model, ** NIM – not in model 
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TABLE 4.4: Summary of weighted clinical risk scores and β-coefficients from final reduced models for Ct and GC infections combined 
and Ct infection alone, by gender 
 FEMALES  MALES 
 Ct and/or GC* Ct**  Ct and/or GC** Ct** 
 RS (β) RS (β)  RS (β) RS (β) 
Age ≤ 25 2 (0.78) 2 (1.08)  2 (1.18) 2 (1.15) 
Single    1 (0.54) 1 (0.58) 
High school or less 1 (0.47) 1 (0.72)    
New sex partner within past 2 years 2 (0.60) 1 (0.68)  1 (0.72) 1 (0.71) 
Non-ED as primary source for healthcare  1 (0.71)    
No antibiotic use past month    1 (0.63) 1 (0.68) 
Dysuria or discharge past 3 months 1 (0.30) 1 (0.32)  1 (0.87) 1 (0.72) 
NOTES:  * Weighted risk score calculated assigned a weight of 1 to predictors with β <0.5 and a weight of 2 to predictors with β 
>=0.5, ** Weighted risk score calculated assigned a weight of 1 to predictors with β <1.0 and a weight of 2 to predictors with β >=1.0 
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TABLE 4.5: Validation of previously developed screening criteria for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) 
infection in present emergency department sample 
  18-31 year olds  18-31 year old females 
Predictor 
 
Previous 
(n=427) 
OR (95% CI) 
Present 
(n=4,436) 
OR (95% CI) 
 
Previous 
(n=274) 
OR (95% CI) 
Present 
(n=2,419) 
OR (95% CI) 
Age < 25  2.20 (1.18, 4.11) 2.44 (1.97, 3.03)    
New sex partner past 90 days     2.23 (1.03, 4.83) 1.62(1.26, 2.10) 
> 1 sex partner past 90 days  2.22 (1.21, 4.06) 1.48 (1.22, 1.81)    
History of STD  2.01 (1.11, 3.61) 1.32 (1.09, 1.60)  2.02 (0.94, 4.29) 1.24 (0.97, 1.58) 
       
    
Model performance (screening using any one factor)*:    
  % (95% CI) % (95% CI)  % (95% CI) % (95% CI) 
   Sensitivity  93 (84, 97) 92 (89, 94)  78 (63, 89) 69 (64, 74) 
   Specificity  12 (9, 16) 21 (19, 22)  38 (32, 44) 42 (40, 44) 
NOTES:  OR = odds ratio, CI = confidence interval 
* Model performance based on previously proposed screening criteria of using any one of the following factors: age <25, new sex 
partner in past 90 days, > 1 sex partner past 90 days, or a history of STD.6 
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FIGURE 4.1.  Trade-off between false negatives (FN) and false positives (FP) required to 
justify screening for Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) across 
varying prevalence of infection among females 
 
Notes:  FN = patient who is infected but infection remains undetected because patient is not 
screened, FP = patient who is not infected but is screened based on selected screening 
algorithm. 
 
 
 
 
 
 
CHAPTER FIVE:  FOLLOW-UP OF CHLAMYDIAL AND GONOCOCCAL INFECTIONS 
IDENTIFIED IN AN EMERGENCY DEPARTMENT 
 
 
 
5.1. Abstract 
Objectives:  (1) To examine two potentially important factors, healthcare coverage and 
reporting the ED as a primary source for healthcare, influencing successful treatment and 
follow-up of ED-identified chlamydial and gonococcal infections.  (2) To describe the 
geospatial distribution of ED-identified infections. 
 
Methods: Adult patients aged 18-35 years attending an urban ED were screened for Ct and 
GC; participants provided specimens for amplification testing and completed a brief 
questionnaire.  Patients testing positive were contacted by DIS and notified of their infection 
status.  Analyses focus on infected patients for whom we have treatment and follow-up 
information.  We used generalized linear models with log link and binomial error distribution 
to estimate risk ratios and 95% confidence intervals.  We used ArcGIS to create count maps 
of ED-identified infections. 
 
Results:  Of 5,537 patients successfully screened in the ED, 348 (6.3%) patients tested 
positive for Ct, 143 (2.6%) tested positive for GC, and 43 (0.8%) tested positive for both.  
Approximately two-thirds (65%) of infected patients were female and the majority (91%) 
were African American.  The average age was 23.2 ± 4.6 years.  Approximately 40% of 
infected patients reported they were not covered by Medicaid, Medicare, HMO, or private 
insurance and 20% reported the ED as their primary source for healthcare.  DIS attempted 
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to contact all patients identified as infected during their ED visit.  Of the 532 infected 
patients, 278 (52%) received treatment as part of the study, 87 (16%) received treatment 
during their ED visit, and 63 (12%) reported receiving treatment elsewhere (either at a local 
health department or at their primary care physician).  DIS were unable to locate 53 (10%) 
infected patients, 6 (1%) patients were out of jurisdiction, 7 (1%) were in jail or a 
rehabilitation facility, 21 (4%) patients were located but refused treatment, and 17 (3%) did 
not show up for their scheduled follow-up appointment.   
 
Among infected persons with no healthcare coverage, 25% (n=56) were untreated 
compared to 15% (n=47) of infected patients who reported having healthcare coverage (RR: 
1.7, 95% CI: 1.2, 2.3).  Among patients reporting the ED as a primary source for healthcare, 
26% (n=27) had untreated infections compared to 18% (n=77) of infected patients reporting 
they usually get healthcare from a private doctor, a clinic, an HMO, or no usual place (RR: 
1.4, 95% CI: 1.0, 2.1).  Both of these relationships varied by reported recent antibiotic use.  
We were able to match 90% of reported addresses to a location.  Visual inspection of a 
count map of ED-identified infections reveals a clear clustering of infection in the immediate 
vicinity of the ED, based on qualitative measures. 
 
Conclusions:  EDs often serve as primary care sites for difficult-to-reach populations. We 
were able to successfully locate and treat the greater part of ED-identified infections.  
However, one-fifth of infected patients did not receive treatment.  Untreated infections were 
a combination of persons not located and persons refusing treatment.  ED-based screening 
programs can benefit from integration with local public health infrastructure to improve 
notification and treatment services.   
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5.2. Introduction 
The majority of screening programs for Chlamydia trachomatis (Ct) and Neisseria 
gonorrhoeae (GC) are based in clinics, schools, and communities.3  However, a handful of 
studies have evaluated the feasibility and acceptability of moving Ct and GC screening into 
Emergency Departments (ED).4, 6, 40, 65, 83, 93  All of these ED based studies have screened for 
Ct and GC using nucleic acid amplification testing (NAAT) technology which requires 
laboratory support and several days to generate results to confirm a diagnosis.  Given the 
lag time between submitting the biologic specimen for testing and receiving test results, 
most asymptomatic infections cannot be treated at the time of the ED visit.  Consequently, a 
system to ensure treatment for infected persons must be in place.  Relatively little is known 
about the factors influencing successful treatment of persons in this situation. 
 
While the studies that have generated the ED-specific screening data have principally relied 
on dedicated research staff for recruiting, screening, interviewing, and providing follow-up 
test results and services, the information from these studies can help improve upon current 
public health prevention and control efforts.  Characterizing individuals not likely to seek 
treatment or follow-up services could help target patients who would benefit from being sent 
home with appropriate treatment and instructed to only take the antibiotic if they are notified 
of infection.  Patients less likely to return for treatment and follow-up services may also 
benefit from more intensive counseling on the importance of treating the infection and 
notifying sexual partners at the time of screening.  
 
Using data from patients screened for Ct and GC in a busy urban ED, we examined two 
potentially important factors influencing successful treatment, healthcare coverage and 
reporting the ED as a primary source for healthcare.  We described the geographic 
distribution of Ct and GC infections identified in the ED and compared the geospatial 
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distribution of patients who received treatment to those who did not.  We also evaluated the 
influence of distance from a patient’s reported home address to the ED on the likelihood of 
their return for treatment and follow-up services  
 
5.3. Methods 
5.3.1. Study Design 
This short duration prospective cohort study is part of a larger study of patients presenting at 
the Johns Hopkins Hospital Adult Emergency Department in Baltimore, MD between 
November 2002 and February 2005.  The study comprised two phases, a screening phase 
and a follow-up phase.  Patients were eligible for participation in the screening phase of the 
study if they were between 18 and 35 years of age, English-speaking, and sexually active in 
the past 90 days.  Employees and students of Johns Hopkins, and patients who were 
critically ill, intoxicated, or presenting for acute psychiatric or STI-related symptoms were 
excluded.  Participants in the screening phase completed a brief demographic and 
behavioral audio computer-assisted self-interview (ACASI) questionnaire and provided self-
collected specimens for Ct and GC NAAT.  Participants with a positive NAAT result who 
were administered antibiotics during their ED visit were considered treated and not eligible 
to participate in the follow-up phase of the study.  Analyses presented in this paper focus on 
participants who tested positive for Ct or GC during the screening phase of the study and 
the status of their treatment, regardless of whether or not they participated in the follow-up 
phase of the study. 
 
Patients testing positive for Ct or GC were contacted by Disease Intervention Specialists 
(DIS) and notified of their infection status.  Patients were offered follow-up examination, 
additional STI testing, and treatment at the Johns Hopkins General Clinical Research Center 
(GCRC).  Patients were also informed by DIS that they could seek treatment for their 
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infection at the local health department or from their primary health provider.  Patients who 
attended the GCRC were offered participation in the follow-up phase of the research study.  
Participants completed an extensive ACASI questionnaire, provided specimens for 
additional testing, underwent a physical examination, and received antibiotic treatment for 
their infection.  In addition, sexual partner(s) of positive participants were recruited for the 
follow-up phase of the study.  Further details of the complete study protocol are described 
elsewhere.87   
 
The Institutional Review Boards of RTI International, The Johns Hopkins Hospitals, and the 
University of North Carolina at Chapel Hill approved the study protocol.  In compliance with 
Maryland state laws, all Ct and GC infections were reported to the Baltimore City Health 
Department.  Written informed consent was obtained from all study participants.   
 
5.3.2. Main Factors of Interest and Outcome Measure 
The first main factor of interest, healthcare coverage, was dichotomized into no healthcare 
coverage or having Medicare, Medicaid, a Health Maintenance Organization (HMO), or 
private insurance.  The second main factor of interest, reporting the emergency department 
as a primary source for healthcare, was also analyzed dichotomously.   
 
The main outcome measure was not receiving treatment or follow-up services for Ct and/or 
GC infections identified in the ED.  There were five possible outcomes for patients who 
tested positive during their ED screening: (1) patient received treatment during their ED visit, 
(2) patient returned to receive treatment and follow-up services at the GCRC, (3) patient was 
located by DIS and reported receiving treatment at the local health department or from their 
primary care provider, (4) patient was located by DIS but refused treatment and follow-up 
services, or (5) DIS was unable to locate the patient.  We evaluated the outcome as a 
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dichotomous measure examining those who did not receive treatment or follow-up because 
they refused or were not located compared to patients who received treatment, regardless 
of where treatment was received.   
 
5.3.3. Statistical Analysis 
All analyses were conducted using Stata version 8.0 (StataCorp, College Station, TX).  We 
used generalized linear models with log link and binomial error distribution to estimate 
unadjusted and adjusted risk ratios (RRs) and 95% confidence intervals (CIs) to describe 
the association between the two main factors of interest, healthcare coverage and reporting 
the ED as the primary source for healthcare, and failure to receive treatment.80  Additionally, 
we used a modified Poisson regression model without an offset to estimate risk ratios to 
ensure that results were comparable to the estimates from the generalized linear models.81   
 
We determined which demographic and behavioral factors could potentially modify the 
association between each of the two main factors of interest and not receiving treatment or 
follow-up services by examining the main associations stratified by the categories of each 
potential effect measure modifier.  For variables which we identified as potential effect 
measure modifiers, we constructed product-interaction terms between the main factor of 
interest and each effect measure modifier.  We included in the starting model those 
interaction terms with p-values less than α=0.20.90  We then examined variables not 
identified as effect measure modifiers as potential confounders and included in the starting 
multivariable model those variables which appeared to confound the main association.  We 
constructed two models: one examining the main association between patient’s healthcare 
coverage and not receiving treatment or follow-up services and one examining the 
association between reporting the ED as the primary source for healthcare and not receiving 
treatment or follow-up services for the Ct and/or GC infection identified in the ED. 
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We used a backward elimination strategy based on a change in estimate criteria to remove 
from the starting models variables which did not modify or confound the main associations.  
Product-interaction terms were removed if their likelihood ratio test p-value was greater than 
α=0.10.  Covariates were not retained in the model if their removal changed the main 
association by less than 10% overall or in any stratum of the interacting variables.95  
 
5.3.4. Geographic Information Systems Analysis 
We used ArcGIS and Environmental Systems Research Institute’s (ESRI) StreetMap 2006 
to geocode self-reported residential addresses to physical locations (ESRI, Redlands, CA).  
The geocoded addresses were then projected into North American Datum 1983 State Plane 
Meters and straight line distance to the emergency department was calculated by spatially 
joining the physical address of the ED to the geocoded addresses.  We evaluated the 
influence of distance on patients’ likelihood of not receiving treatment or follow-up services, 
in addition to evaluating distance as a potential confounding variable in our models of the 
main associations.  Graphically, we created a count map of infections within each census 
block group.  We also created count maps for infections which received treatment and 
follow-up and those that did not.  To visually compare the distributions of treated and 
untreated infections based on qualitative factors, we calculated the proportion of untreated 
infections within each census block group and generated a proportion map.  In addition, we 
calculated Moran coefficients to measure clustering within each census block group.96  A 
Moran coefficient close to +1 indicates positive spatial dependence while a coefficient close 
to zero indicates no spatial dependence. 
 
5.4. Results 
5.4.1. Overall Population 
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A total of 7,532 eligible patients were approached to participate, of whom 6,195 patients 
consented to enroll in the ED screening phase of the study (82% response rate).  Of the 
consenting patients, 494 patients (8% of those consenting) did not complete the ACASI 
questionnaire and 164 patients (3%) did not provide a specimen or provided an unusable 
specimen (e.g. specimen leaked during transport).  A total of 5,537 patients completed the 
ACASI questionnaire and provided a self-collected vaginal swab or urine specimen which 
yielded a valid test result.  Among participating patients, the overall prevalence of Ct and GC 
infection was 9.6%.   
 
5.4.2. Study Population Characteristics  
Of the patients screened in the ED, 348 (6.3%) patients tested positive for Ct, 143 (2.6%) 
tested positive for GC, and 43 (0.8%) tested positive for both.  Our analyses focus on 
patients who tested positive for either Ct or GC or both and for whom we have information 
on their treatment and follow-up status.  Approximately two-thirds (65%) of infected patients 
were female and the majority (91%) were African American (Table 5.1).  The average age of 
patients testing positive for Ct and/or GC was 23.2 ± 4.6 years.  Only 13% of infected 
patients reported having more than a high school education and 86% reported never being 
married.  Nearly half (45%) of infected patients reported being previously diagnosed with 
either Ct or GC, while 30% reported having a partner or not knowing if their partner had 
been previously diagnosed with an STI.  A little more than one-fifth (22%) of patients 
reported using antibiotics in the three months prior to their ED visit. 
 
5.4.3. Main Factors of Interest 
Roughly 40% of infected patients reported that they were not covered by Medicaid, 
Medicare, an HMO, or private insurance during their ACASI interview in the ED (Table 5.1).  
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In response to the question “Where do you usually go to get your health care?” 20% of 
infected patients reported the emergency department as their primary source for healthcare.   
 
5.4.4. Outcome: Failure to receive treatment and follow-up for ED-identified infection 
DIS attempted to contact all patients identified as Ct or GC infected during their ED visit.  
DIS followed standard disease notification procedures which involved up to 20 telephone 
contact attempts and certified mail.  If telephone contact was unsuccessful, the DIS sent a 
notification letter via certified mail.  The mean number of attempted DIS contacts was 2.9 ± 
2.6 contacts.  The mean number of days between screening in the ED and notification of 
results for patients not treated in the ED and whom DIS was able to locate was 19 days 
(range 6 – 251 days). 
 
Overall, 20% of infected patients did not receive treatment or follow-up services for 
infections identified in the ED.  Of the 532 infected patients, 278 (52%) received treatment 
and follow-up services at the GCRC, 87 (16%) received treatment during their ED visit, and 
63 (12%) reported receiving treatment elsewhere (either at the local health department or at 
their primary care physician).  DIS were unable to locate 53 (10%) infected patients, 6 (1%) 
patients were out of the DIS jurisdiction, 7 (1%) patients were in jail or a rehabilitation facility, 
21 (4%) patients were located but refused treatment, and 17 (3%) did not show up for their 
scheduled GCRC visit.  For our analyses, we assumed that patients not located by DIS did 
not receive treatment for their infection.   
 
5.4.5. Healthcare coverage status and not receiving treatment or follow-up services for ED-
identified infections 
Among infected persons with no healthcare coverage, 56 (25%) did not receive treatment 
compared to 15% of infected patients who reported having Medicaid, Medicare, an HMO, or 
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private coverage (RR: 1.7, 95% CI: 1.2, 2.3; Table 5.2).  This relationship varied by recent 
antibiotic use.  Among patients who reported using antibiotics in the three months prior to 
their ED visit, the risk of not receiving treatment or follow-up services was four times higher 
(RR: 4.3, 95% CI: 1.5, 12.0) for patients who also reported that they did not have healthcare 
coverage compared to patients who reported some type of health coverage and antibiotic 
use.  On the other hand, patients reporting no antibiotic use in the past three months and no 
healthcare coverage were only 1.4 (95% CI: 1.0, 2.1) times as likely not to receive treatment 
or follow-up services for their infections compared to infected patients reporting healthcare 
coverage and no antibiotic use.  Gender, race, age, marital status, education, previous Ct or 
GC diagnosis, having a partner diagnosed with an STI in the past two years, reporting the 
ED as the primary source for healthcare, and distance to the ED did not appear to confound 
the association between healthcare coverage and not receiving treatment or follow-up 
services for ED-identified infections. 
 
5.4.6. ED as primary source for healthcare and not receiving treatment or follow-up for ED-
identified infections 
Among patients reporting the ED as their main source for healthcare, 27 (26%) did not 
receive treatment or follow-up services for their infection compared to 18% of infected 
patients reporting that they usually get healthcare from a private doctor, a clinic, an HMO, or 
no usual place (RR: 1.4, 95% CI: 1.0, 2.1; Table 5.3).  The association between reporting 
the ED as the primary source for healthcare and not receiving treatment or follow-up also 
varied by reported antibiotic use.  Patients reporting antibiotic use in the three months prior 
to their ED visit who also reported the ED as their primary source for healthcare were three 
times as likely (RR: 3.1, 95% CI: 1.4, 6.7) not to receive treatment or follow-up for their 
infections compared to patients reporting antibiotic use but who reported a non-ED source 
as their primary healthcare source.  However, among patients reporting no antibiotic use in 
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the three months prior to their ED visit, the risk of not receiving treatment or follow-up was 
similar for those reporting the ED as their primary source for healthcare and those reporting 
a non-ED source (RR: 1.1, 95% CI: 0.7, 1.8).  Healthcare coverage was the only covariate 
that appeared to confound the main association between reporting the ED as the primary 
source for healthcare and not receiving treatment or follow-up for ED-identified infections in 
both strata of antibiotic use.   
 
5.4.7. Geospatial Analysis 
We were able to match 90% of reported addresses to a location.  Our count map of 
chlamydial and gonococcal infections detected in the ED shows weak positive clustering 
with a Moran coefficient of 0.15 (Figure 5.1).  Visual inspection of the count maps for 
infections that were treated and those not treated reveals similar distributions based on 
qualitative comparison (Figures 5.2 and 5.3).  The map of the proportion of untreated 
infections within each census block provides an objective method to visually compare the 
spatial distributions of the treatment outcome (Figure 5.4).  Furthermore, the median 
distance to the ED was similar for patients receiving treatment and follow-up services and 
those who did not with a linear travel distance of 2.66 and 2.89 kilometers, respectively 
(Wilcoxon rank-sum p-value=0.44). 
 
5.5. Discussion 
EDs often serve as primary care sites for difficult-to-reach populations.  In our study, we 
were able to successfully locate and treat the greater part of infections identified in the ED.  
However, while the majority of patients (80%) received treatment for their Ct and/or GC 
infection, one-fifth of infected patients did not.  We examined factors associated with failure 
to receive treatment and follow-up services to elucidate ways to ensure treatment for these 
difficult-to-reach persons. 
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Our results demonstrate a clear association between patients’ lack of healthcare coverage 
and the risk of not receiving treatment and follow-up services for an ED-identified Ct and/or 
GC infection.  This association differs depending on recent antibiotic use.  Our results also 
suggest an association between reporting the ED as a primary source for healthcare and the 
risk of not receiving treatment or follow-up services for an infection.  However, this 
association may only hold true among patients reporting antibiotic use in the three months 
prior to Ct and GC screening in the ED. 
 
The varying effect of recent antibiotic use on the relationship between the two main factors 
of interest, healthcare coverage and reporting the ED as a primary source for healthcare, 
and failure to receive treatment and follow-up is somewhat puzzling.  Among patients 
reporting antibiotic use in the three months prior to their ED visit, 28% of those reporting no 
healthcare coverage and 35% of those reporting the ED as their main source for healthcare 
did not receive treatment or follow-up services.  In the ACASI interview, we defined 
antibiotics to participants as “pills or tablets taken by mouth that are prescribed by a doctor 
or nurse to treat a number of bacterial infections including sinus infections, pneumonia, 
bladder infections, and STIs”.  It is possible that patients reporting recent antibiotic use 
assumed their antibiotic use was sufficient for treatment of the current Ct or GC infection.  
However, given that untreated infections comprised patients who refused treatment and 
patients whom DIS was unable to locate, it is difficult to determine whether this association 
is a result of the patient refusing treatment or an artifact of that patient not being located. 
 
Previous studies examining treatment and follow-up of infections identified in an ED setting 
have focused mainly on the clinical management of patients with little attention to factors 
that contribute to the failure to receive appropriate treatment.58, 66  In addition, previous data 
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have been primarily derived from symptom-based testing in the ED and therefore cannot be 
extended to the majority of infected patients who present without symptoms.57, 66, 97, 98  We 
excluded patients who were seeking care for STI-related symptoms during their ED visit 
making our study population more representative of the general population.  While 16% of 
our study population did in fact receive antibiotic treatment during their ED visit, their primary 
reason for seeking care at the ED was not for STI-related complaints. 
 
Another potential barrier to receiving treatment may have been the lag time between 
screening in the ED and notifying infected individuals of their results.  In our study, the mean 
number of days between screening and result notification was 18.6 days (range 6 to 251 
days).  Due to the fact that the biological specimens collected in the Johns Hopkins Hospital 
ED were shipped to the University of North Carolina at Chapel Hill’s Microbiology laboratory 
for NAAT processing, our lag time was a little longer than it would have been had testing 
been performed onsite.  However, the lag time would be similar if the specimens were 
processed by a commercial laboratory.  The lack of a rapid test with sufficient sensitivity and 
specificity necessitates some lag time if NAATs are used to screen which eliminates the 
possibility of on-site treatment for the majority of asymptomatic infections.  Nevertheless, the 
lag time could be significantly shortened if specimens were tested onsite and dedicated 
laboratory technicians were available to perform the assays and report results.     
 
While our maps reveal a clear clustering of chlamydial and gonococcal infections around the 
ED, the geospatial distribution of treated and untreated infections does not appear to be 
influenced by proximity to the ED.  We did not find an association between distance to the 
ED and risk of not receiving treatment and follow-up services for the ED-identified infection.  
We calculated linear distance between self-reported residential address and the emergency 
department and not the actual travel distance.  Although actual travel distance might have 
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been preferable, given that we did not find an association with failure to receive treatment 
and follow-up services using linear distance, it seems highly unlikely there would be an 
association using actual travel distance.  
 
As STI screening programs continue to expand and emergency departments are utilized 
more often as screening venues, serious consideration must be given to ensuring treatment 
and follow-up of all detected infections.  This study demonstrates that it is possible to 
provide appropriate treatment and follow-up services to a large number of infections 
identified in an ED setting.  While our study relied on dedicated research staff and 
resources, there were still patients that we were unable to locate.  Follow-up services and 
treatment of ED-identified infections can benefit from integrated partnerships with local 
health departments in addition to intensive STI counseling for patients at highest risk for not 
receiving treatment at the time of the screening.  While all patients would benefit from 
intensive STI prevention and control messages, targeting those at highest risk when they do 
access healthcare in the emergency department may be the only opportunity to intervene 
with this difficult-to-reach population. 
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TABLE 5.1:  Distribution of the main outcome, main factors of interest and other covariates 
among patients testing positive for chlamydial and/or gonococcal infections in an 
Emergency Department (ED) 
  Total N (%) 
Main Outcome   
Disposition of ED-identified infection   
   Did not receive treatment and follow-up services 
   Received treatment and follow-up services 
 
 
 
104 (19.6) 
428 (80.4) 
 
Main Factors of Interest   
Health Coverage 
   No Coverage 
   Medicare/Medicaid/HMO/Private 
    
 
 
223 (42.0) 
308 (58.0) 
 
Primary Source for Healthcare 
   Emergency Department 
   Non-Emergency Department 
 
 
 
105 (19.7) 
427 (80.3) 
Covariates   
Gender 
   Females 
   Males 
 
 
344 (64.7) 
188 (35.3) 
Race 
   African American 
   Non-African American 
 
 
482 (90.6) 
50 (9.4) 
Age 
   18 – 20 
   21 – 25 
   26 – 30 
   31 – 35 
 
 
189 (35.5) 
203 (38.2) 
 87 (16.4) 
53 (9.9) 
Marital Status 
   Never Married 
   Married/Divorced/Widowed 
 
 
456 (85.7) 
76 (14.3) 
Educational Attainment 
   High School or less 
   More than High School   
 
 
462 (86.8) 
70 (13.2) 
Previously Diagnosed with Ct or GC 
   Ever 
   Never 
 
 
239 (45.2) 
290 (54.8) 
Antibiotic Use 
   Within the past 3 months 
   Not within the past 3 months 
 
 
114 (21.5) 
416 (78.5) 
Partner diagnosed with STI 
   Yes or Don’t Know 
   No 
 
 
161 (30.3) 
371 (69.7) 
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TABLE 5.2: Association between healthcare coverage status and not receiving treatment or follow-up services for chlamydial and/or 
gonococcal infections identified in the emergency department, crude and stratified by antibiotic use 
  No Treatment or follow-up 
N (%) 
 Risk Ratio (95% CI) 
Main Factor of Interest     
Healthcare Coverage 
   No coverage 
   Medicare/Medicaid/HMO/Private 
    
  
56 (25.2) 
47 (15.3) 
  
1.7 (1.2, 2.3) 
1.0 (ref) 
Stratified by Antibiotic Use     
Self-reported Antibiotic Use in Past 3 Months     
   Healthcare Coverage     
      No coverage  15 (28.3)  4.3 (1.5, 12.0) 
      Medicare/Medicaid/HMO/Private  4 (6.7)  1.0 (ref) 
     
No Antibiotic Use in Past 3 Months     
   Healthcare Coverage     
      No coverage  41 (24.4)  1.4 (1.0, 2.1) 
      Medicare/Medicaid/HMO/Private  42 (17.1)  1.0 (ref) 
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TABLE 5.3: Association between reporting the emergency department as primary source for healthcare and not receiving treatment 
or follow-up services for chlamydial and/or gonococcal infections, crude and stratified by antibiotic use 
  No Treatment or follow-up 
N (%) 
 Unadjusted  
Risk Ratio (95% CI) 
 Adjusted* 
Risk Ratio (95% CI) 
Main Factor of Interest       
Primary Source for Healthcare 
   Emergency Department 
   Non-Emergency Department 
 
  
27 (25.7) 
77 (18.0) 
  
1.4 (1.0, 2.1) 
1.0 (ref) 
  
1.2 (0.8, 1.8) 
1.0 (ref) 
Stratified by Antibiotic Use       
Self-reported Antibiotic Use in Past 3 Months       
  Primary Source for Healthcare       
      Emergency Department   9 (34.6)  3.1 (1.4, 6.7)  2.5 (1.1, 5.5) 
      Non-Emergency Department  10 (11.4)  1.0 (ref)  1.0 (ref) 
       
No Antibiotic Use in Past 3 Months       
  Primary Source for Healthcare       
      Emergency Department  18 (22.8)  1.1 (0.7, 1.8)  1.0 (0.6, 1.6) 
      Non-Emergency Department  66 (19.6)  1.0 (ref)  1.0 (ref) 
       
NOTES: * adjusted for healthcare coverage status 
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FIGURE 5.1: Counts of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) 
infection detected in an emergency department among 18 to 35 year old patients by census 
block group, Baltimore, Maryland, 2002-2005   
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FIGURE 5.2:  Counts of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) 
infection receiving treatment and follow-up services after detection in an emergency 
department among 18 to 35 year old patients by census block group, Baltimore, Maryland, 
2002-2005 
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FIGURE 5.3:  Counts of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) 
infection not receiving treatment and follow-up services, due to both refusal of treatment and 
failure to locate patient, after detection in an emergency department among 18 to 35 year 
old patients by census block group, Baltimore, Maryland, 2002-2005 
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FIGURE 5.4: Proportion of Chlamydia trachomatis (Ct) and Neisseria gonorrhoeae (GC) 
infection not receiving treatment and follow-up services, due to both refusal of treatment and 
failure to locate patient, after detection in an emergency department among 18 to 35 year 
old patients within census block groups, Baltimore, Maryland, 2002-2005 
 
 
 
 
 
 
 
 
  
 
CHAPTER SIX:  CONCLUSIONS 
 
 
In a busy urban emergency department, approximately 10% of patients were unknowingly 
infected with chlamydial and/or gonococcal infection.  Given the asymptomatic nature of 
most chlamydial infections and many gonococcal infections, screening interventions are 
critical for early detection and treatment of these bacterial infections.  EDs often serve 
populations with limited access to regular healthcare and, therefore, have been proposed as 
promising venues for screening interventions.  Many of those at highest risk for sexually 
transmitted infections do not have access to regular healthcare.  Consequently, their visit to 
the ED may be the only opportunity to intervene with Ct and GC screening. 
 
Regular access to healthcare may also affect the risk of not receiving treatment and follow-
up services once an infection is detected.  While the majority of our study participants 
received treatment and follow-up services for their infections, approximately one-fifth of 
patients did not.  To effectively control transmission of these infections and the potential 
progression of serious clinical sequelae, all detected infections must be appropriately 
treated.  Treatment should be available to all infected individuals, regardless of the status of 
their healthcare coverage.  In addition to treatment, prevention and control information 
should be easily accessible. 
 
All four of our ED-specific risk score algorithms reemphasize the conclusion that screening 
based on age alone is a reasonable strategy in situations where selective screening is 
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necessary.84  In a busy ED, where the time necessary to take an extensive sexual history is 
in high demand, it is useful to know that the predictive power gained beyond screening using 
age alone is minimal.  Screening based on age alone also removes the stigma associated 
with taking a sexual history and allows for easier incorporation of Ct and GC screening into 
routine ED services.  Additionally, the similarity between our algorithms developed for Ct 
and GC infections combined and our algorithms for Ct infection alone provide assurances 
for the use of Ct-specific screening criteria to also screen for GC.   
 
We did not include patients’ racial and ethnic background during the development of our risk 
score algorithms due to the potential sensitivity of proposing selectively screening based on 
an individual’s racial and ethnic background.  However, we did evaluate the impact of racial 
background on our models in the development process and there was no detectable 
difference given the high uniformity of race in this ED population (approximately 80% of our 
study population was African American).  While the inclusion of racial and ethnic information 
did not impact our models, the high proportion of African Americans in our population has 
implications for the generalizability of our results.  Our results may only be applicable in 
populations with similar demographic characteristics. 
 
Cost is a major determining factor in the decision to undertake any screening program. 
Screening for chlamydial and gonococcal infections is a cost-effective method to reduce the 
prevalence of infection and subsequent clinical sequelae.  Nevertheless, the cost of 
screening activities must be absorbed somewhere.  Whether the screening costs are borne 
by the emergency department, by local public health infrastructure, by a federal agency, or 
by a private organization will ultimately be the deciding factor in resource-limited ED 
settings.  Because the cost-savings associated with averted long term complications of 
chlamydial and gonococcal infections are not realized directly by the ED, it may be difficult 
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to convince ED administrators that Ct and GC screening should be incorporated into routine 
services.  Additionally, ED administrators may not view preventive medicine as their 
responsibility.  In determining the “optimal” screening policy for EDs, our results suggest 
that, across varying prevalence of infection, the consequences of undetected infections 
must substantially outweigh the cost of unnecessarily testing a large number of uninfected 
individuals to justify implementing Ct and GC screening as part of routine ED services.    
 
However, if the decision to include Ct and GC screening as part of routine ED services is 
made, serious consideration must be given to ensuring appropriate treatment and follow-up 
of all detected infections.  Follow-up services and treatment of ED-identified infections can 
benefit from integrated partnerships with local health departments in addition to intensive 
STI counseling for patients at highest risk for not receiving treatment at the time of the 
screening.  While all patients would benefit from intensive STI prevention and control 
messages, targeting those at highest risk when they do access healthcare in the emergency 
department may be the only opportunity to intervene with this difficult-to-reach population. 
 
In a small case-series study conducted in this same Baltimore ED, 34 (out of a sample of 
100) patients delayed treatment for two weeks or longer for STI related symptoms.99  
Reasons for not seeking treatment sooner included: no insurance, no money, not bothered 
that much by symptoms, and had other more important things to do.  Delayed treatment can 
lead to transmission of infection to sexual partners and continued STI morbidity.  When the 
opportunity presents itself, patients must be counseled on the importance of treatment and 
follow-up of any identified infection. 
 
We excluded patients who were seeking care at the ED for STI related symptoms from our 
study population.  This exclusion makes our ED population more comparable to the general 
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population than to the typical STD clinic population.  However, this exclusion criterion was 
based on self-reported symptoms which may be subject to under-reporting given that some 
symptoms can be non-specific.     
 
The geospatial distribution of infections detected in the ED was determined by geocoding 
self-reported residential addresses.  There are several limitations associated with using 
residential address to map infection.  The first, and most limiting, is that residential address 
may not accurately indicate where infection was acquired.  Although residential address 
may not indicate where infection was acquired, it serves as a good indication of the 
distribution of infection among patients who access the ED for healthcare.  Second, many of 
those at high risk for STI and who are most likely to access the ED for healthcare are 
homeless, do not live at a fixed residential address, or have multiple temporary residential 
addresses.  Of the 532 participants included in our treatment outcome analysis, 479 
addresses geocoded to a physical location.  However, of the 479 geocoded addresses, only 
one address geocoded to an alternative address which was either provided by the 
participant or matched by the DIS to the patient’s medical chart. 
 
This dissertation research adds to the small, but growing, body of literature focusing on ED 
based screening for chlamydial and gonococcal infections.  We evaluated the effectiveness 
of ED-specific screening criteria and provided a framework within which the implementation 
of routine Ct/GC screening in an ED setting can be considered.  We described the 
association between healthcare access and failure to receive treatment and follow-up 
services for ED-identified infections.  Lastly, we provided visual representations of the 
geospatial distribution of chlamydial and gonococcal infections detected in the ED. 
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Given that the prevalence of Ct and GC infections remains unacceptably high for two 
infections that are easily treated with antibiotics, yet have the potential to result in serious 
reproductive consequences if left untreated, and that screening rates are low despite current 
recommendations, moving screening programs into settings most likely to reach those at 
highest risk is a worthy public health endeavor.   
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APPENDIX ONE:  Variable Descriptions and Coding Schemes 
 
Demographic variables include age, race/ethnicity, educational attainment, and current 
marital status. 
 
Age:  Participants were asked to report their age which was originally coded as a continuous 
variable ranging from 18 to 35.  To determine how age should be coded for our predictive 
models we coded age several different ways and plotted age against the predicted 
probability of infection.  We examined the following coding schemes:  dummy quartiles, 
continuous, squared, linear splines, quadratic splines, and restricted quadratic splines.  See 
Figures A.1 through A.4 for graphs of different coding schemes.   
 
Race/Ethnicity: Participants were asked to self identify as being black or African-American, 
white, Asian, or other.  We dichotomized this variable into African-American and non-African 
American given that a large proportion of the study population (over 80%) was African-
American.  Given the potential sensitivity of screening for an STI based on an individual’s 
racial and ethnic background, we developed models with and without this variable to 
evaluate its impact on the prediction of infection. 
 
Educational Attainment: Participants were asked to report the highest grade or level of 
school that they had completed.  Response options included: 8th grade or less, some high 
school but did not graduate, high school graduate or GED, some college or 2-year college, 
4-year college graduate, and more than 4-year college degree.  We collapsed categories 
based on the distribution of responses. 
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Marital Status:  Participants were asked to identify themselves as being married, separated, 
divorced, widowed, or never married.  We collapsed categories based on the distribution of 
responses and the substantive meaning of the categorizations. 
 
Sexual behavior variables include condom use, number of sex partners, and most recent 
occurrence of a new sex partner. 
 
Condom use: Participants were asked: “Thinking about the last 5 times you had sex, how 
many of those times did you use a condom?”  Responses were originally coded as 
continuous ranging from 0 to 5.  We dichotomized this variable into “5 out 5” and “Less than 
5 out of 5” because it was a meaningful categorization of risk. 
 
Number of sex partners: Participants were asked: “In the past two years, how many different 
people have you had sex with?  By sex, we mean vaginal or anal sex.”  Responses were 
originally coded continuously ranging from 0 to 99.  Participants were then asked: “Of those 
partners within the past 2 years, how many have you had sex with in the past 3 months?”  
Responses were also coded continuously ranging from 0 to 99.  We categorized both these 
variables because they were not linear in the logit when coded continuously in addition to 
the need to make the variable of more practical use in an ED setting. 
 
New sex partners: Participants were asked: “When was the last time you had a new sex 
partner? A new sex partner is someone you had sex with that you never had sex with 
before.”  Response options included: past 3 months, 3 to 6 months, 6 months to 1 year, 1 to 
2 years, and 2 or more years.  We will consider collapsed categories based on the 
distribution of responses.   
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Partner characteristic variables include sexual contact with an STI-infected person and 
sexual contact with a person who has concurrent partners. 
 
Partner with STI: Participants were asked: “Were any of your sex partners during the past 2 
years diagnosed with a sexually transmitted disease or HIV?”  Response options included: 
yes, no, and don’t know.  We collapsed the “yes” and “don’t know” categories and 
dichotomized the variable into “no” and “yes/don’t know” to address the issue of perceived 
risk.  
 
Partner had other partners: To evaluate the status of partner concurrency, participants were 
asked: “As far as you know, did any of your partners in the past 3 months have other sexual 
partners during the same time that you were having sex with them?”  Response options 
included: yes, no, and don’t know.  We dichotomized this variable as above. 
 
Healthcare utilization variables include current healthcare coverage status, primary 
healthcare seeking behaviors, reason for ED visit, and antibiotic use. 
 
Healthcare coverage status: To evaluate healthcare coverage, participants were asked the 
following questions: “Are you covered by any private health insurance that pays any part of 
your hospital or doctor bills?”, “Are you covered by Medicaid?”, “Are you covered by 
Medicare?”, and “Are you covered by a health maintenance organization or HMO?”  
Responses from these four questions were combined to create one insurance status 
variable.  The variable was then dichotomized into “no healthcare coverage” and 
“Medicaid/Medicare/HMO/private”. 
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Primary source for health care: To determine the status of participants’ primary health care 
seeking behaviors, participants were asked: “Where do you usually go to get your health 
care?”  Response categories included: private doctor, clinic, ED, HMO, and no usual place.  
We evaluated this variable as categorical in addition to evaluating the dichotomization of 
“ED as primary source” and “non-ED as primary source” for some analyses. 
 
Reason for ED visit: To evaluate the reason for participants’ current visit to the ED, 
participants were asked the following question: “Did you come to the emergency department 
today because you thought that you had an emergency condition that could only be taken 
care of in an emergency department?”  Participants who responded negatively were then 
asked: “If you did not think that you needed to go to an emergency department, why did you 
come here?”  Response options included: regular doctor not available, no regular doctor, 
more convenient, or no transportation available to go somewhere else.  We collapsed 
across categories based on the distribution of responses. 
 
Antibiotic use: To evaluate antibiotic use, participants were asked to report if they had ever 
taken an antibiotic and to report the most recent use.  Antibiotics were defined to 
participants as: “pills or tablets taken by mouth that are prescribed by a doctor or nurse to 
treat a number of bacterial infections including sinus infections, pneumonia, bladder 
infections, and STIs.”  Response options for last antibiotic use included: past week, 1 week 
to 1 month, 1 to 3 months, 3 to 6 months, 6 months to 1 year, and 1 or more years.  We 
collapsed across categories based on the distribution of responses. 
 
STI health status variables include a history of chlamydial or gonococcal infection and 
genitourinary symptoms which could be indicative of an STI. 
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History of self-reported Ct/GC: Participants were asked: “Has a doctor or nurse ever told you 
that you had gonorrhea or chlamydia?”  Participants who reported positively were then 
asked: “When was the last time a doctor or nurse told you that you had gonorrhea or 
chlamydia?”  Response categories included: past 3 months, 3 to 6 months, 6 months to 1 
year, 1 to 2 years, and 2 or more years.  We collapsed categories based on the distribution 
of responses. 
 
Genitourinary symptoms: To evaluate symptom status, participants were asked to report 
several symptoms which could be suggestive of a current STI.  For female participants, 
symptoms included: burning during urination, vaginal discharge, pain during intercourse, 
vaginal bleeding between periods, and abdominal or lower abdomen pain.  For male 
participants, symptoms included: burning during urination, penile dripping or discharge, and 
testicular pain.  If participants reported experiencing a symptom they were then asked to 
report the most recent occurrence of the symptom.  Response categories included: past 3 
months, 3 to 6 months, 6 months to 1 year, 1 to 2 years, and 2 or more years.  Based on the 
distribution of responses we combined symptoms together and collapsed across time 
categories. 
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FIGURE A.1.1: Different coding schemes plotting age against the predicted probability of Ct 
and GC infection combined among females 
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FIGURE A.1.2: Different coding schemes plotting age against the predicted probability of Ct 
and GC infection combined among males 
 
 
 
 
 
 
 
 
 
 
 101
FIGURE A.1.3: Different coding schemes plotting age against the predicted probability of Ct 
infection alone among females 
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FIGURE A.1.4: Different coding schemes plotting age against the predicted probability of Ct 
infection alone among males 
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APPENDIX TWO:  Bootstrap estimates for 1000 samples with replacement 
 
 
 
TABLE A.2.1: Bootstrap estimates for female Ct and GC infections combined models 
 Observed Bias Error 95% CI 
Using Risk Score ≥ 2     
  Prevalence 11.3427 -0.0409 0.5832 10.1982, 12.4872 
  Sensitivity 95.4819 0.0216 1.1584  93.2087, 97.7551 
  Lower limit for sensitivity  92.6575 0.0354 1.4201 89.8708, 95.4443 
  Upper limit for sensitivity 97.4496 0.0001 0.8727 95.7371, 99.1620 
  Specificity 14.6436 0.0453 0.6957 13.2783, 16.0088 
  Lower limit for specificity 13.3045 0.0444 0.6684 11.9929, 14.6161 
  Upper limit for specificity 16.0629 0.04593 0.7215 14.6471, 17.4787 
     
Using Risk Score ≥ 5     
  Prevalence 11.3427 -0.0409 0.5832 10.1982, 12.4872 
  Sensitivity 52.7108  0.0575 2.6358 47.5384, 57.8833 
  Lower limit for sensitivity  47.1862  0.0495 2.6345 42.0165, 52.3559 
  Upper limit for sensitivity 58.1867  0.0643 2.5978 53.0890, 63.2844 
  Specificity 69.0173  0.0691 0.9258 67.2005, 70.8342 
  Lower limit for specificity 67.1982  0.0711 0.9396 65.3543, 69.0421 
  Upper limit for specificity 70.7935  0.0669 0.9100 69.0077, 72.5793 
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TABLE A.2.2: Bootstrap estimates for male Ct and GC infections combined models 
 Observed Bias Error 95% CI 
Using Risk Score ≥ 2     
  Prevalence 7.7523 -0.0071 0.5335 6.7054, 8.7992 
  Sensitivity 99.4413  0.0261 0.5390 98.3836, 100.499 
  Lower limit for sensitivity  96.9268  0.0862 0.9150 95.1312, 98.722 
  Upper limit for sensitivity 99.9859 -0.0446 0.1095 99.7709, 100.201 
  Specificity 9.4836 -0.0022 0.6072 8.2920, 10.6752 
  Lower limit for specificity 8.2722 -0.0015 0.5707 7.1524, 9.3920 
  Upper limit for specificity 10.8077 -0.0030 0.6422 9.5475, 12.0678 
     
Using Risk Score ≥ 5     
  Prevalence 7.7523 -0.0071 0.5335 6.7054, 8.7992 
  Sensitivity 64.2458  0.0119 3.5557 57.2683, 71.2233 
  Lower limit for sensitivity  56.7546  0.0136 3.6695 49.5538, 63.9555 
  Upper limit for sensitivity 71.2565  0.0069 3.3406 64.7010, 77.8120 
  Specificity 69.3427 -0.2812 0.9820 67.4158, 71.2697 
  Lower limit for specificity 67.3356 -0.0283 0.9980 65.3771, 69.2940 
  Upper limit for specificity 71.2965 -0.0279 0.9633 69.4062, 73.1868 
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TABLE A.2.3: Bootstrap estimates for female Ct infection alone models 
 Observed Bias Error 95% CI 
Using Risk Score ≥ 2     
  Prevalence 7.6158 0.0051 0.4851 6.6639, 8.5677 
  Sensitivity 99.0991 -0.0105 0.6289 97.8648, 100.333 
  Lower limit for sensitivity  96.7837  0.0266 0.9876 94.8456, 98.7218 
  Upper limit for sensitivity 99.8907 -0.0648 0.2182 99.4626, 100.319 
  Specificity 4.9759  0.0228 0.4317 4.1300, 5.8218 
  Lower limit for specificity 4.1854  0.0217 0.3970 3.4063, 4.9645 
  Upper limit for specificity 5.8659  0.0238 0.4641 4.9553, 6.7766 
     
Using Risk Score ≥ 5     
  Prevalence 7.6158  0.0051 0.4851 6.6639, 8.5677 
  Sensitivity 59.9099  0.1010 3.3572 53.3219, 66.4979 
  Lower limit for sensitivity  53.1406  0.1086 3.4035 46.4621, 59.8198 
  Upper limit for sensitivity 66.4105  0.0895 3.2328 60.0667, 72.7543 
  Specificity 68.2882 -0.0247 0.8829 66.5556, 70.0207 
  Lower limit for specificity 66.4928 -0.0249 0.8960 64.7347, 68.2510 
  Upper limit for specificity 70.0436 -0.0244 0.8680 68.3403, 71.7470 
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TABLE A.2.4: Bootstrap estimates for male Ct infection alone models 
 Observed Bias Error 95% CI 
Using Risk Score ≥ 2     
  Prevalence 6.5972 0.0168 0.5311 5.555, 7.6394 
  Sensitivity 100 0 0 100, 100 
  Lower limit for sensitivity  97.6023 -0.0099 0.1957 97.2184, 97.9863 
  Upper limit for sensitivity 100 0 0 100, 100 
  Specificity 9.4331 0.0384 0.6423 8.1727, 10.6935 
  Lower limit for specificity 8.2308 0.0367 0.6040 7.0456, 9.4160 
  Upper limit for specificity 10.7471 0.0401 0.6789 9.4150, 12.0792 
     
Using Risk Score ≥ 5     
  Prevalence 6.5972  0.0168 0.5311 5.555, 7.6394 
  Sensitivity 64.4737 -0.0321 3.9302 56.7614, 72.1860 
  Lower limit for sensitivity  56.3117 -0.0172 4.0629 48.3388, 64.2846 
  Upper limit for sensitivity 72.0593 -0.0483 3.6660 64.8654, 79.2532 
  Specificity 69.0985  0.0296 1.0355 67.0665, 71.1306 
  Lower limit for specificity 67.0979  0.0302 1.0524 65.0327, 69.1632 
  Upper limit for specificity 71.0470  0.0290 1.0159 69.0535, 73.0405 
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APPENDIX THREE:  Trade-off between false negatives and false positives across varying 
prevalence of infection 
 
 
TABLE A.3.1: Trade-off for female Ct and GC infections combined models 
Using Risk Score ≥ 2, Sensitivity = 0.95, 1-Specificity = 0.85 
Prevalence # FNno screen Weight # FNrisk score≥2 # FPrisk score≥2 # total errors 
0.02 20 43.84 1 833 834 
0.04 40 21.47 2 816 818 
0.06 60 14.02 3 799 802 
0.08 80 10.29 4 782 786 
0.10 100  8.05 5 765 770 
0.12 120  6.56 6 748 754 
0.14 140  5.50 7 731 738 
      
Using Risk Score ≥ 5, Sensitivity = 0.53, 1-Specificity = 0.31 
Prevalence # FNno screen Weight # FNrisk score≥5 # FPrisk score≥5 # total errors 
0.02 20 28.66 9.4 303.8 313.2 
0.04 40 14.04 18.8 297.6 316.4 
0.06 60  9.16 28.2 291.4 319.6 
0.08 80  6.73 37.6 285.2 322.8 
0.10 100  5.26 47.0 279.0 326.0 
0.12 120  4.30 56.4 272.8 329.2 
0.14 140  3.59 65.8 266.6 332.4 
      
 
 
FIGURE A.3.1: Graph of trade-off for female Ct and GC infections combined models 
FEMALES Ct and GC combined: Trade-off between FN and FP 
across varying prevalence of infection
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TABLE A.3.2: Trade-off for male Ct and GC infections combined models 
Using Risk Score ≥ 2, Sensitivity = 0.99, 1-Specificity = 0.91 
Prevalence # FNno screen Weight # FNrisk score≥2 # FPrisk score≥2 # total errors 
0.02 20 45.04 0.2 891.8 892 
0.04 40 22.06 0.4 873.6 874 
0.06 60 14.40 0.6 855.4 856 
0.08 80 10.57 0.8 837.2 838 
0.10 100  8.27 1.0 819.0 820 
0.12 120  6.74 1.2 800.8 802 
0.14 140  5.65 1.4 782.6 784 
      
Using Risk Score ≥ 5, Sensitivity = 0.64, 1-Specificity = 0.31 
Prevalence # FNno screen Weight # FNrisk score≥5 # FPrisk score≥5 # total errors 
0.02 20 23.73  7.2 303.8 311 
0.04 40 11.63 14.4 297.6 312 
0.06 60  7.59 21.6 291.4 313 
0.08 80  5.57 28.8 285.2 314 
0.10 100  4.36 36.0 279.0 315 
0.12 120  3.55 43.2 272.8 316 
0.14 140 2.98 50.4 266.6 317 
      
 
 
FIGURE A.3.2: Graph of trade-off for male Ct and GC infections combined models 
MALES Ct and GC combined: Trade-off between FN and FP 
screening across varying prevalence
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TABLE A.3.3: Trade-off for female Ct infection alone models 
Using Risk Score ≥ 2, Sensitivity = 0.99, 1-Specificity = 0.95 
Prevalence # FNno screen Weight # FNrisk score≥2 # FPrisk score≥2 # total errors 
0.02 20 47.02 0.2 931 931.2 
0.04 40 23.03 0.4 912 912.4 
0.06 60 15.03 0.6 893 893.6 
0.08 80 11.04 0.8 874 874.8 
0.10 100  8.64 1.0 855 856.0 
0.12 120  7.04 1.2 836 837.2 
0.14 140  5.89 1.4 817 818.4 
      
Using Risk Score ≥ 5, Sensitivity = 0.60, 1-Specificity = 0.32 
Prevalence # FNno screen Weight # FNrisk score≥5 # FPrisk score≥5 # total errors 
0.02 20 26.13  8 313.6 321.6 
0.04 40 12.80 16 307.2 323.2 
0.06 60  8.36 24 300.8 324.8 
0.08 80  6.13 32 294.4 326.4 
0.10 100  4.80 40 288.0 328.0 
0.12 120  3.91 48 281.6 329.6 
0.14 140  3.28 56 275.2 331.2 
      
 
 
FIGURE A.3.3: Graph of trade-off for female Ct infection alone models 
FEMALES Ct alone: Trade-off between FN and FP across 
varying prevalence
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TABLE A.3.4: Trade-off for male Ct infection alone models 
Using Risk Score ≥ 2, Sensitivity = 1.0, 1-Specificity = 0.91 
Prevalence # FNno screen Weight # FNrisk score≥2 # FPrisk score≥2 # total errors 
0.02 20 44.59 0 891.8 891.8 
0.04 40 21.84 0 873.6 873.6 
0.06 60 14.26 0 855.4 855.4 
0.08 80 10.47 0 837.2 837.2 
0.10 100  8.19 0 819.0 819.0 
0.12 120  6.67 0 800.8 800.8 
0.14 140  5.59 0 782.6 782.6 
      
Using Risk Score ≥ 5, Sensitivity = 0.64, 1-Specificity = 0.31 
Prevalence # FNno screen Weight # FNrisk score≥5 # FPrisk score≥5 # total errors 
0.02 20 23.73  7.2 303.8 311 
0.04 40 11.63 14.4 297.6 312 
0.06 60  7.59 21.6 291.4 313 
0.08 80  5.57 28.8 285.2 314 
0.10 100  4.36 36.0 279.0 315 
0.12 120  3.55 43.2 272.8 316 
0.14 140  2.97 50.4 266.6 317 
      
 
 
FIGURE A.3.4: Graph of trade-off for male Ct infection alone models 
MALES Ct alone: Trade-off between FN and FP across varying 
prevalence
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